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Abstract 
 
There is heightened interest to diversify the range of crystal forms exhibited by 
active pharmaceutical ingredients (APIs) in the pharmaceutical industry.  The crystal 
form can be regarded as the Achilles’ heel in the development of an API as it directly 
impacts the physicochemical properties, performance and safety of the API.     This is of 
critical importance since the crystal form is the preferred method of oral drug delivery by 
industry and regulatory bodies.  The ability to rationally design materials is a lucrative 
avenue towards the synthesis of functional molecular solids with customized 
physicochemical properties such as solubility, bioavailability and stability.  
Pharmaceutical cocrystals have emerged as a new paradigm in pharmaceutical solid form 
development because they afford the discovery of novel, diverse crystal forms of APIs, 
generate new intellectual property and modify physicochemical properties of the API.  In 
addition, pharmaceutical cocrystals are amenable to design from first principles of crystal 
engineering.   
This dissertation focuses on the crystal engineering of multi-component crystal 
forms, in particular pharmaceutical cocrystals and crystalline hydrates.   It addresses:  (i) 
the factors involved in the selection of cocrystal formers (ii) design strategies for APIs 
that exhibit complexity, (iii) the role of water molecules in the design of multi-component 
crystal forms and (iv) the relationship between the crystal structure and thermal stability 
of crystalline hydrates.   
ix 
 
In general, cocrystal former libraries have been limited to pharmaceutically 
acceptable substances.  It was investigated to expand this library to include substances 
with an acceptable toxicity profile such as nutraceuticals.  In other words, can 
nutraceuticals serve as general purpose cocrystals formers?  The model compounds, 
gallic acid and ferulic acid, were selected since they possess the functional moieties 
carboxylic acids and phenols, that are known to form persistent supramolecular synthons 
with complementary functional groups such as basic nitrogen and amides.  The result 
yielded pairs of cocrystals and revealed the hierarchical nature of hydrogen bonding 
between complementary functional groups.   
In general, pharmaceutical cocrystals have been designed by determining the 
empirical guidelines regarding the hierarchy of supramolecular synthons.  However, this 
approach may be inadequate when considering molecules that are complex in nature, 
such as those having a multiplicity of functional groups and/or numerous degrees of 
conformational flexibility.  A crystal engineering study was done to design multi-
component crystal forms of the atypical anti-psychotic drug olanzapine.  The approach 
involved a comprehensive analysis and data mining of existing crystal structures of 
olanzapine, grouped into categories according to the crystal packing exhibited.  The 
approach yielded isostructural, quaternary multi-component crystal forms of olanzapine.  
The crystal forms consist of olanzapine, the cocrystal former, a water molecule and a 
solvate. 
The role of water molecules in crystal engineering was addressed by investigating 
the crystal structures of several cocrystals hydrates and their related thermal stability.   
x 
 
The cocrystal hydrates were grouped into four categories based upon the thermal stability 
they exhibit and it was concluded that no structure/stability correlations exist in any of 
the other categories of hydrate.  A Cambridge Structural Database (CSD) analysis was 
conducted to examine the supramolecular heterosynthons that water molecules exhibit 
with two of the most relevant functional groups in the context of active pharmaceutical 
ingredients, carboxylic acids, and alcohols.  The analysis suggested that there is a great 
diversity in the supramolecular heterosynthons exhibited by water molecules when they 
form hydrogen bonds with carboxylic acids or alcohols. This finding was emphasized by 
the discovery of two polymorphs of gallic acid monohydrate to it the first tetramorphic 
hydrate for which fractional coordinates have been determined.  Analysis of the crystal 
structures of gallic acid monohydrate polymorphs revealed that forms I and III exhibit the 
same supramolecular synthons but different crystal packing and forms II and IV exhibit 
different supramolecular synthons.  Therefore, the promiscuity of water molecules in 
terms of their supramolecular synthons and their unpredictable thermal stability makes 
them a special challenge in the context of crystal engineering. 
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Chapter 1:  Introduction 
1.1 Relevance of crystal form in pharmaceutical science 
The selection of crystal form is a critical step in pharmaceutical development.  
Indeed, crystallization is generally used as a separation or purification method in the 
production of substances due to its high stability and ease in processing.  The vast 
majority of active pharmaceutical ingredients (APIs) are isolated in the solid form and the 
selection of crystal form is invariably considered to be the first step in formulation 
development (Fig. 1.1).  Therefore, the control of the crystal form and the size and shape 
of the crystal become of paramount interest.  The crystal form influences downstream 
process applications such as filtration, drying, milling, granulation and tableting.  More 
importantly, physicochemical properties such as bioavailability, solubility and dissolution 
rate are strongly dependent on the crystal form of the API.   
 
 
Figure 1.1:  Steps in the selection of crystal form in the development of the API. 
 
The ubiquitous nature of APIs i.e. they contain multiple hydrogen bonding sites 
makes them inherently predisposed to form multiple crystal forms.  These crystal forms 
include but are not limited to salts, hydrates, solvates, polymorphs and pharmaceutical 
2 
 
cocrystals (Fig.1.2).  The diversity of crystal forms of an API creates opportunities to 
customize the physicochemical properties of that API.  High-throughput screening has 
been generally used to explore crystal forms of APIs since it accelerates the discovery of 
diverse crystal forms and provides an understanding of the factors that govern 
crystallization.
1
  However, in vitro screening in solvents such as dimethyl sulfoxide and 
polyethylene glycol to identify as many hits as possible resulted in new drug candidates 
exhibiting poor aqueous solubility and/or dissolution rate.
2
    As bioavailability is a 
function of solubility, poor oral bioavailability has become characteristic of many new 
drug candidates.
 3,4
  In fact, drug candidates with poor bioavailability are the primary 
reason why 41% of new drug candidates fail in preclinical and clinical development (Fig. 
1.3)
5
and 90% of new drug candidates fall into BCS class II and class IV (Figure 1.4).
6
    
Therefore, from a crystal engineering perspective, the design of pharmaceutical solids 
with desired physicochemical properties becomes relevant.   
 
 
Fig. 1.2:  Schematic representation of the types of crystal forms exhibited by APIs. 
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Figure 1.3:  Reasons why new drug candidates fail in development. 
 
 
Figure 1.4:  Comparison of BCS classification of marketed drugs and new drug 
candidates. 
 
1.2 Drug Dissolution and Bioavailability 
Drug dissolution was first modeled by Noyes and Whitney.  They proposed the Noyes 
and Whitney equation where the rate of dissolution is proportional to the difference 
between the solution concentration at time t and the equilibrium solubility.
7
  This 
equation was later modified to become the Noyes-Whitney-Nernst equation and denoted 
that, with all other parameters being constant, the rate of drug dissolution is proportional 
to the thermodynamic solubility of the drug.
8
   Amidon and coworkers developed the 
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Biopharmaceutical Classification System (BCS) which proposes that the bioavailability 
of the API is a function of solubility or dissolution rate and membrane permeability.
9
  
According to the BCS system, APIs are categorized into four categories:  (1) high 
permeability, high solubility; (2) high permeability, low solubility; (3) permeability, high 
solubility and (4) low permeability, low solubility (Figure 1.5).  A drug substance is 
considered highly soluble when the highest dose strength is soluble in < 250 ml water 
over a pH range of 1 to 7.5 and highly permeable when the extent of absorption in 
humans is determined to be > 90% of an administered dose, based on mass-balance or in 
comparison to an intravenous reference dose.   
 
 
Fig. 1.5:  The Biopharmaceutical Classification System (BCS) 
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1.3 Types of Crystal Forms 
 
1.3.1 Hydrates and Solvates  
Solvates are molecular complexes where one or more solvent molecules are 
incorporated within the crystal lattice in stoichiometric proportions.  It is referred to as a 
hydrate when the solvent of crystallization is a water molecule.
10
  Hydrates represent 
about 10% of the structures archived in the CSD
11
 and it has been suggested that 
approximately 33% of organic compounds form hydrates, whereas solvates are less 
prevalent (10%).
12
  The adventitious nature of the water molecule allows it to be easily 
incorporated within the crystal lattice due to its size and versatile hydrogen bonding 
capabilities.  The water molecule can act as a guest where the water molecule is not 
firmly bound within the crystal structure or the water molecule can play an integral role 
to stabilize the crystal structure where there is an imbalance in the number of hydrogen 
bond and donors.
13
   APIs are prone to hydrate formation due to their inherent nature, i.e. 
they possess many hydrogen bond donors and acceptors and it is estimated that 
approximately one third of APIs are capable of forming hydrates during pharmaceutical 
manufacturing.
14
  Stability is a matter of concern for pharmaceutical hydrates because 
they can undergo solid phase transition under storage conditions and therefore alter the 
physicochemical properties.  
 
1.3.2 Polymorphs 
Polymorphism refers to the ability of a compound to exist in more than one 
crystal form.  The earliest reported polymorphic compound was benzamide discovered in 
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1832 by Wöhler and Liebig.  The phenomenon of polymorphism is a scientific challenge 
in the pharmaceutical industry and its adverse effects is revealed in the prominent 
examples of rantidine hydrochloride and ritonavir.
15,16
  The relevance of polymorphism 
was heightened by the patent litigation between Glaxo and Novopharm, where Glaxo 
sued for the infringement of its patent of a form II polymorph of rantidine hydrochloride.  
In addition to legal and regulatory implications, polymorphism also affects the 
physicochemical properties of an API such as dissolution rate.  This is exemplified by the 
API ritonavir where after the launch of the drug ritonavir by Abbot Laboratories, a more 
stable, previously unknown form II was discovered.  The dissolution properties of the 
latter were significantly different in comparison to the previous form forcing the 
company to reformulate the API resulting in a loss of sales.  Polymorphism can be 
divided into two classes:  packing polymorphism and conformation polymorphism.  
Packing polymorphism occurs when rigid molecules exhibit more than one packing 
arrangement caused by different supramolecular synthons or they retain the same 
supramolecular synthons but exhibit different crystal packing.  Conformational 
polymorphism is when molecules exists in more than one conformation in the solid state 
and is exemplified by 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile, ROY 
where it crystallizes in eight polymorphic forms. 
 
1.3.3 Salts 
Salt formation has been the primary means to modify the physicochemical 
properties of an API.  Indeed, approximately, 50% of marketed APIs are administered as 
salts.
17
   Salts are formed when a compound that is ionized in solution forms a strong 
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ionic interaction with an oppositely charged counterion.  Its success and stability is 
dependent on the relative strength of the acid or base and the acidity and basicity constant 
of the components involved.
18
  The general rule of thumb for salt formation is that the 
acid ionization constant, pKa, between the acid and the base should be different by at least 
two or three units.  The limitation of this is that the pKa values are only valid under the 
solution equilibrium conditions at which they were determined.  Salt forms are 
advantageous because they enhance the physicochemical properties of the API and their 
preparation is relatively simple.  However, its formation is limited to the presence of 
ionizable groups on the API and it compromises the intrinsic activity of the API.  In 
addition, although hydrochloride salts are the most common anionic salt forming species, 
they may not necessarily enhance the solubility in a chloride containing solvent medium 
because of common ion effect.  For example, the hydrochloride salt of the Prazosin, has 
an aqueous solubility of   1.4 mg/ml but 0.037 mg/ml solubility in 0.1M HCl solution.   
 
1.3.4 Pharmaceutical Cocrystal 
Pharmaceutical cocrystals,
19 ,20
 multi-component crystals in which at least one 
component is a neutral API  and the cocrystal former is a pharmaceutically acceptable ion 
or molecule, have recently been added to the landscape of crystal forms of APIs.
 
 Early 
literature on pharmaceutical cocrystals focused primarily on the crystal structures of 
pharmaceutical cocrystals.  Perhaps, the earliest reported pharmaceutical cocrystal is the 
1934 French patent which disclosed cocrystals of barbiturates.
21
  Caira and others 
reported the potential of complexes of sulphonamide drugs in drug development
22
 and 
Whitesides reported the supramolecular assemblies of melamine and babiturates 
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derivatives.
23
  In 2002, Oswald and coworkers demonstrated the cocrystallization of the 
drug paracetamol
24
 and shortly after, Zaworotko et al reported pharmaceutical cocrystals 
of the APIs ibuprofen, flurbiprofen and aspirin.
25
  In recent years, pharmaceutical 
cocrystals have emerged as a new paradigm in pharmaceutical solid form development as 
they are an effective means of altering physicochemical properties such as solubility, 
bioavailability and stability of APIs.
 26
  Indeed, the significant impact of pharmaceutical 
cocrystals has resulted in the recent release of a FDA draft guidance concerning the 
regulatory classification of pharmaceutical cocrystals.
27
  The draft proposed the definition 
and classification of pharmaceutical cocrystals. 
Pharmaceutical cocrystals are advantageous in four-fold because:  (1) they are 
susceptible to design since the directionality and selectivity of the hydrogen bond allows 
for the rational construction of new functional solid forms (2) enables a diverse number 
of crystal forms of a given API from a wide range of pharmaceutically acceptable 
cocrystal formers and the formation is not limited to the nature of the molecule e.g. 
presence of ionizable groups on the API  (3) fine-tunes the structural and 
physicochemical properties of the solid and therefore creates intellectual property 
opportunities and (4) the intended intrinsic activity of the API is preserved.   
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1.4 Supramolecular Chemistry 
Molecular chemistry, thus, has established its power over the covalent bond.  The time 
has come to do the same over non-covalent intermolecular forces.  Beyond molecular 
chemistry based on the covalent bond there lies the field of supramolecular chemistry, 
whose goal is to gain control over the intermolecular bond. 
Jean Marie Lehn
28
 
 
Supramolecular chemistry, described as “chemistry beyond the molecule” 
expands over several science disciplines such as classical inorganic and organic 
chemistry, material science and physics.  The beginning of supramolecular chemistry can 
be traced back to the late 19
th
 century through the introduction of transition-metal 
coordination chemistry by Werner,
29
 Emil Fischer’s lock and key mechanism in enzyme 
reactions and the discovery of cyclodextrins by Hebd.   However, it was the pioneering 
works of Pederson,
 30
 Lehn and Cram in the discovery of crown ethers that ignited 
interest in supramolecular chemistry.  Supramolecular chemistry extends beyond the 
realm of atomic and molecular chemistry to afford highly complex, well-defined 
supramolecular entities.
31
  It emphasizes the use of intermolecular interactions in the self-
assembly of molecules governed by their chemical and geometrical factors.   
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Intermolecular Interaction Strength (kJ/mol) 
Ion-Ion 100-350 
Ion-Dipole 50-200 
Hydrogen Bond 4-120 
Dipole-Dipole 5-50 
π- π Stacking <50 
Van der Waals <5 
Table 1.1:  Strength of Non-covalent Interactions. 
 
These intermolecular interactions include hydrogen bonding, π- π stacking, 
coordinative bonds, dipolar interactions and van der Waals forces (Table 1.1).
32
  They 
play a critical role in the structure and function of biological systems such as protein 
folding and enzyme catalysis.  The hydrogen bond is perhaps the most significant 
intermolecular interaction and is fundamental in the stability of the double helix structure 
in DNA, the best known self-assembling supramolecular entity in nature.  The hydrogen 
bond is defined as, “an attractive interaction between a hydrogen atom from a molecule 
or a molecular fragment X–H in which X is more electronegative than H, and an atom or 
a group of atoms in the same or a different molecule, in which there is evidence of bond 
formation.”33   The hydrogen bond has been extensively studied and is viewed as a 
synthetic vector in the structural assembly of molecules.  Its strength, selectivity and 
directionality influence the crystal packing of molecules thereby determining its physical 
and chemical properties.  Research in the understanding of the nature and role of these 
11 
 
intermolecular interactions in the context of crystal packing stealthily increased with the 
advancement of X-ray crystallography, giving rise to a new scientific genre, crystal 
engineering.  
 
1.5 Crystal Engineering 
“Crystallization of organic ions with metal-containing complex ions of suitable sizes, 
charges and solubilities results in structures with cells and symmetries determined chiefly 
by packing of complex ions. These cells and symmetries are to a good extent 
controllable:  hence crystals with advantageous properties can be ‘engineered’…” 
 Pepinsky, 1955 
 
Crystal engineering, synonymous to solid state supramolecular synthesis, focuses 
on the synthesis and design of functional crystalline materials. It stems from the premise 
that the crystal, described as the perfect supermolecule,
34
 supermolecule par excellence,
 35
  
is the de facto manifestation of self-assembly of molecules.   Although the term was 
coined in 1955 by Pepinsky,
 36
 it is the pioneering work by Gerald Schmidt in 1971 that is 
generally considered to be the birth of crystal engineering.
 37
   Schmidt studied 
photodimerization reactions of olefins in the solid state and determined that the 
photoreactivity was governed by the stereochemical vicinity between olefins rather than 
intrinsic electronic properties.  He postulated that photochemical reactions occurred only 
if the distance between the C=C double bonds of adjacent molecules was between 3.5 and 
12 
 
4.2 Å and the stereochemistry at the nearest neighbor double bonds were either 
antiparallel (related by a crystallographic center of symmetry) or parallel (related by a 
translation axis).   Schmidt’s work revealed that the physical and chemical properties of 
crystalline solids were dependent on the packing of the molecules within the crystal 
lattice.  Soon after, the focus shifted from the engineering of structures to the engineering 
of properties and in 1989, Desiraju defined crystal engineering as, “the understanding of 
intermolecular interactions in the context of crystal packing and the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties.”38    Subsequently, the field has matured into an interdisciplinary scientific 
discipline with a wide scope of applications in areas such as catalysis,
39
 energy storage,
40
 
electronics
41
 and pharmaceutics.
42
  
 
1.6 Graph Set Analysis and Supramolecular Synthon  
Seminal works by Etter and Desiraju were pivotal in understanding the nature of 
intermolecular interaction in molecular crystals.   Etter used mathematical graph theory to 
delineate the nature of hydrogen bonding patterns and classify them into simpler 
notations known as graph set analysis.  Graph set analysis is written in the format, G
a
d (n) 
where G is the hydrogen bond motif and can be denoted as one of the following:  (1) D:  
dimer or finite (2) C:  chain (3) S:  intramolecular (4) R:  ring.  The number of acceptors, 
donors and atoms are denoted a, d and n respectively.  Through extensive studies of 
hydrogen bonding patters of organic crystals, she devised empirical rules to define the 
hierarchical nature of hydrogen bonds:  (1) all good proton donors and acceptors are used 
(2) six membered ring intramolecular hydrogen bonds will form in preference to 
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intermolecular hydrogen bonds and (3) the best proton donors and acceptors remaining 
after intramolecular hydrogen bonding will form intermolecular hydrogen bonds with 
each other.
43
  Desiraju coined the term “supramolecular synthon” and it is defined as, 
“structural units within supermolecules which can be formed and/or assembled by known 
or conceivable intermolecular interactions.
44
  The concept was extended by Zaworotko 
into two distinct classes: supramolecular homosynthons and supramolecular 
heterosynthons.
 45
   Supramolecular homosynthon is the result of intermolecular 
interactions between identical self-complementary functional groups such as carboxylic 
acid dimers and amide dimers (Figure 1.6), whereas supramolecular heterosynthon are 
intermolecular interactions between two or more different but complementary functional 
groups such as carboxylic acid-amide and carboxylic acid-aromatic nitrogen (Figure 1.7).  
The concepts of graph set analysis and supramolecular synthons and the systematic 
analysis of existing crystal structures is essential in crystal engineering and can be used as 
a prototypal tool in the design of crystalline solids.  This is facilitated through the 
technique of database mining using the Cambridge Structure Database.
46
   
 
1.7 Cambridge Structural Database 
The Cambridge Structural Database (CSD) is an established primary repository 
for the experimentally determined 3D structures of organic and organometallic 
compounds.   It is a structural visualization and analysis software developed by the 
Cambridge Crystallographic Data Centre (CCDC).  The CCDC was founded by the 
University of Cambridge in 1965 with the primary objective:  “advancement and 
promotion of the science of chemistry and crystallography for the public benefit.”  The 
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CSD comprises of over half a million structures making it a comprehensive and highly 
curated scientific resource for crystal engineering.   The CSD facilitates reliable and fast 
retrieval, visualization and analysis of experimentally measured crystallographic data to 
further understand the behavior of molecules and intermolecular forces within a crystal.  
This knowledge is fundamental to crystal engineering as it gives information concerning 
the type of intermolecular interaction, the geometrical preferences, the directional 
characteristics and the types of supramolecular synthons involved. 
 
 
 
 
 
 
 
Figure 1.6:  Illustration of (a) carboxylic acid supramolecular homosynthon and (b) 
amide supramolecular homosynthon. 
 
 
 
         
(a)        (b)  
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Figure 1.7:  Illustration of (a) carboxylic acid-amide supramolecular heterosynthon and 
(b) carboxylic acid-aromatic nitrogen supramolecular heterosynthon. 
 
1.8 Cocrystal 
 
1.8.1 Definition 
The definition of cocrystal is an active subject of debate.  The debate started in 
2003 when Desiraju expressed the unsuitability of the term co-crystal and suggested that 
the previously used terms such as molecular complexes should be adhered to.
47
  Dunitz, 
however, stated that the term molecular complex is too vague and while the term “co-
crystal” is not perfect, it has been irrevocably established.48  He defined a co-crystal as “a 
crystal containing two or more components together.”  Both Dunitz and Desiraju agreed 
that the term should be “co-crystal” in contrast to “cocrystal” to indicate togetherness of 
two components.  Aakeroy offered a more restrictive definition in that the components of 
cocrystals must be neutral and exists as a solid at ambient conditions with a well-defined 
stoichiometry.
49
  However, Bond found this definition unsatisfactory due to the 
restriction that all components must be solid.
50
  Zaworotko proposed the definition, “a 
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stoichiometric multiple component crystal that is formed between two crystalline 
materials that are solids under ambient conditions. At least one of the components is 
molecular (target molecule) and forms a supramolecular synthon with the remaining 
component (cocrystal former).” 
 
1.8.2 History  
The earliest example of a cocrystal was quinhydrone, a complex formed between 
hydroquinone and quinone reported by Wohler in 1844.
51
  Subsequently, other examples 
of cocrystals were reported in the literature but were called organic molecular 
compounds
52
, heteromolecular crystals,
53
 molecular complexes
54
 and addition 
compounds.
55
  The term ‘cocrystal’ was coined in 1967 to describe the hydrogen bonded 
complex formed 9-methyladenine and 1-methylthymine (Fig. 1.8)
56
 and was later 
popularized through the works of Etter.
57
  Cocrystals are of topical interest because they 
create an opportunity to address the hierarchy of intermolecular interactions and they 
have applications in pharmaceutical formulation, non-linear optics and green chemistry.     
 
 
 
 
 
 
 
Figure 1.8:  Interaction between 9-methyladenine and 1-methylthymine molecules. 
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1.8.3 Designing Cocrystals 
The design of cocrystals utilizes the first principles of crystal engineering and 
self-assembly of molecules.  It places emphasis on the hierarchy of supramolecular 
synthons by evaluating the reliability of intermolecular interactions between specific 
functional groups and analysis of the crystal packing.  Design strategies, such as the 
supramolecular synthon approach comprises of examining the arrangement and 
frequency of occurrence of supramolecular synthons formed between functional groups.  
The supramolecular synthon approach consists of the following steps:  (1) identifying the 
functional groups present on the target molecule (2) perform an empirical analysis of the 
supramolecular heterosynthons formed between complementary functional groups of 
experimental crystal structures using the CSD and (3) arrange in hierarchical order the 
robust or commonly occurring supramolecular synthons and select the cocrystal formers 
accordingly.  This method is advantageous in delineating the hierarchy of supramolecular 
synthons between complementary functional groups.
 58
  Bis et al studied the preferential 
interaction between alcohols and aromatic nitrogen, Narom in the presence of cyano 
functional groups.
59
  Shattock and others focused on the ability of alcohols and 
carboxylic acids to form reliable supramolecular heterosynthons in the presence of 
competing functional moieties.
60
  Kavuru and coworkers discussed the formation of 
charge assisted H bonds between carboxylates and weakly acidic hydroxyl moieties.
61
   
 
1.8.4 Cocrystal Synthesis 
Mechanochemistry, grinding of solids, has been used in the preparation of 
cocrystals since the 19
th
 century.  Also known as neat grinding or dry grinding,
 62,63
 it is a 
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cost effective and environmentally-friendly technique and provides a cleaner alternative 
to conventional solution based approaches.  Some of the early examples of cocrystals 
were produced by grinding which include the preparation of the quinhydrone cocrystal,
23
 
charge transfer complexes
64
 and methyladenine and methylthymine cocrystal.
65
  Shan and 
coworkers demonstrated a modified mechanochemistry technique known as solvent drop 
grinding (liquid assisted grinding) where the addition of minute amount of solvent 
increased kinetics of cocrystal formation.
66
  Alternative methods for the preparation of 
cocrystals include melt crystallization, solution based methods such as slow evaporation, 
slurrying and SonicSlurry,
67
 supercritical fluid crystallization,
68
 twin screw extrusion
69
 
and spray drying.
70
  Systematic studies have been implemented to understand the 
thermodynamic factors in the formation of cocrystals.  Nair pioneered reaction 
crystallization, where the formation of the cocrystal is driven by the non-stoichiometric 
concentration of the individual components.
71
    She suggested that the solubility of the 
cocrystal can be represented as the product of the component concentrations. 
   Ksp = [A]
a 
[B]
b     
(1) 
Where [A] and [B] are molar concentrations of individual components at equilibrium 
  Therefore, an increase in the concentration of the more soluble component in excess of 
their stoichiometric composition will lower the solubility of the stable cocrystal and 
hence it will crystallize out of solution.  Chiarella and coworkers used ternary phase 
diagrams to deduce that cocrystal formation takes place in the region of the phase 
diagram where the cocrystal is the stable solid phase.
72
  They rationalized that screening 
of new cocrystal of a particular system should be determined by the relative solubilities 
of the two components rather than stoichiometry.   ter Horst and coworkers determined 
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that cocrystal formation can be assessed by comparing the saturation temperature 
corresponding to where both components are saturated and the saturation temperature of 
the pure components.
73
  Given that the saturation temperature of both components is 
higher than the saturation temperature of pure components indicates that a stable, less 
soluble cocrystal phase has been formed.  Zhang et al reported a suspension/slurry 
technique known as solution mediated phase transformation.
74
  This method is based on 
the principle that when crystals of both single components are present in excess, the 
cocrystal forms spontaneously.   
 
1.9 Impact of Pharmaceutical Cocrystals  
 
1.9.1 Solubility 
One of the earliest examples of the solubility of a drug complex, digoxin-
hydroquinone was reported by Higuchi and Ikeda in 1974.
75
  Although it was not termed 
a cocrystal, the authors showed the improvement of solubility of the complex in 
comparison to the free drug digoxin.  However, itraconazole is considered to be the first 
example of an API that addressed the use of pharmaceutical cocrystals to modify 
physicochemical properties of APIs.  Almarrson et al reported the dissolution studies of 
the antifungal drug itraconazole with 1,4-dicarboxylic acids.  All the cocrystals revealed 
an enhanced dissolution of 4-20 fold higher than the itraconazole free base and the 
dissolution rate of itraconazole-malic acid was comparative to the marketed amorphous 
form (Fig. 1.9). 
76
  In 2004, Childs and others demonstrated the use of pharmaceutical 
cocrystals to significantly modify the physicochemical properties of the API, fluoxetine 
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HCl. 
77
  Fluoxetine HCl was cocrystallized with benzoic acid, succinic acid and fumaric 
acid.  The dissolution profiles of the cocrystals revealed that they had an aqueous 
solubility that was 50% less (benzoic acid), comparable (fumaric acid) or 2 fold higher 
(succinic acid) than the crystalline salt of the API (Fig. 1.10).  An intriguing observation 
in the dissolution profile of the pharmaceutical cocrystal of fluoxetine HCl and succinic 
acid was its “spring and parachute.”   The “spring” illustrates a high energy form of the 
API which enables it to solubilize rapidly and the “parachute” is the transition from high 
energy forms to more stable crystal energy forms.
78
  Since 2003, the ability to increase 
the solubility of APIs via pharmaceutical cocrystals has been reiterated through several 
studies. 
 
 
Fig. 1.9:  Dissolution profile of pharmaceutical cocrystals of itraconazole. 
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1.9.2 Bioavailability 
Seminal studies by Hickey and McNamara demonstrated that pharmaceutical 
cocrystals are a viable method to alter the pharmacokinetic profile of a drug.  Hickey and 
coworkers reported higher exposure levels in dogs of the pharmaceutical cocrystal 
carbamazepine-saccharin in comparison to the marketed anhydrous form.
79
  McNamara 
et al performed bioavailability studies in dogs on a 1:1 pharmaceutical cocrystal 
composing of a sodium channel blocker API and glutaric acid.  The cocrystal exhibited a 
3-fold increase in the plasma concentration in dose levels of 5 and 50mg/kg.  In addition, 
the cocrystal exhibited an increase in the intrinsic dissolution rate of 18 times in contrast 
to the pure drug.
80
  About the same time, In another study, L-883555, a 
phosphodiesterase IV inhibitor was cocrystallized with l-tartaric acid, and the cocrystal 
exhibited an area under the concentration– time curve (AUC) of 5.5 as compared to 0.24 
exhibited by the free base.
81
  Bak et al described the pharmacokinetics of AMG517-
sorbic acid cocrystal in Sprague-Dawley rats and at 500 mg/kg dose, the peak plasma 
concentration of AMG517 in the cocrystal was 7 times higher than the free base.
82
  
Further pharmacokinetic studies of AMG517 with a series of carboxylic acids and amides 
showed improvement.
83 , 84   
Investigation in the dissolution and bioavailability of 
lamotrigine revealed that the anlydrate and monohydrated cocrystal of lamotrigine-
nicotinamide had lower serum concentration than the pure drug although the powder 
dissolution rates were higher.
85
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Fig. 1.10:  Dissolution profile of pharmaceutical cocrystals of fluoxetine HCl. 
 
1.9.3 Hydration Stability 
Hydration stability is relevant in pharmaceutical science because the 
transformation of one crystal form to another jeopardizes the desired physicochemical 
properties of the API.  A prominent example is illustrated by stability studies of six 
pharmaceutical cocrystals of caffeine.  Caffeine, a central nervous system stimulant, 
converts to its hydrated form between relative humidity 75 and 98%.  The study revealed 
that the 2:1 pharmaceutical cocrystal caffeine-oxalic acid was very stable upon exposure 
of 98% relative humidity over seven weeks.
86
  Similar studies were done on four 
pharmaceutical cocrystals of theophylline with oxalic acid, glutaric acid, malonic acid 
and maleic acid.  It was shown that only the pharmaceutical cocrystal theophylline-oxalic 
acid displayed an improvement in the physical stability, the remaining cocrystals had 
similar stability to theophylline.
87
  Other studies demonstrate that carbamazepine-
saccharin cocrystal was physically stable at 60% relative humidity and 75% relative 
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humidity for two weeks, despite the fact that carbamazepine readily forms the dihydrate 
under these conditions.
73
 
 
1.9.4 Mechanical properties 
Pharmaceutical cocrystals can be used to alter the mechanical properties of APIs 
as exemplified by studies involving caffeine-methylgallate cocrystal.  The cocrystals 
showed high tensile strength and improved tableting properties in comparison to the 
individual components.
88
  The improvement in mechanical properties was presumed to be 
attributed to the layered structure of the cocrystal.  Another example is illustrated in the 
study of tablet formation and mechanical properties on pharmaceutical cocrystals of 
paracetamol, form I with naphthalene, theophylline, oxalic acid and acridine.
89
  Three-
layered crystal structures of paracetamol were constructed using only planar cocrystal 
formers and as a result the weak shear planes promoted improved elasticity and 
tabletability. 
 
1.10 Overview of Dissertation 
Pharmaceutical cocrystals have matured to be an integral part of pharmaceutical 
solid form development because they afford the discovery of novel, diverse crystal forms 
of APIs and therefore generate new intellectual property.  In addition, pharmaceutical 
cocrystals have been demonstrated to be a viable approach to profoundly modify the 
physicochemical properties such as solubility/dissolution rate, stability and 
bioavailability.  Consequently, several factors regarding their development and 
application becomes of interest which includes but not limited to:  the selection of 
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potential cocrystal formers, development of cocrystals screening methods, scale-up 
techniques, optimal design, characterization and evaluation of the physicochemical 
properties of cocrystals in comparison to the target molecule.   This dissertation seeks to 
understand design strategies in the supramolecular synthesis of cocrystals and address the 
opportunities and challenges that exist in crystal engineering.   
Chapter 2 demonstrates the use of nutraceuticals as cocrystal formers.  Typically, 
cocrystal formers are limited to pharmaceutically approved carboxylic acids and chemical 
included in the generally regarded as safe (GRAS)
90
 and everything added to food in the 
United States (EAFUS) lists.
91
 However, the library of cocrystal formers can be expanded 
to include other classes of compounds that have an acceptable toxicity profile such as 
nutraceuticals.  The nutraceuticals, gallic acid and ferulic acid were selected since they 
possess phenolic and carboxylic acid moieties that are capable of forming reliable 
supramolecular synthons with complementary functional moieties.  The cocrystals were 
systematically designed by applying the supramolecular synthon approach.   
Chapter 3 reveals a crystal engineering design strategy in the synthesis of 
isostructural pharmaceutical cocrystals of the anti-psychotic API olanzapine.  This 
strategy involved a comprehensive analysis of the crystal packing and hydrogen bonding 
patterns of known crystal structures of olanzapine.  This analysis was utilized to 
synthesize isostructural quaternary multi-component crystal forms of olanzapine.  These 
crystal forms consist of olanzapine, the cocrystal former, a water molecule and a solvate.  
This strategy is particularly effective in the systematic and successful design of 
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pharmaceutical cocrystals of complex APIs that possess multiple functional groups 
and/or conformational flexibility.  
Chapter 4 (Appendix 2) addresses the role of water molecules in crystal 
engineering by studying the relationship between crystal structures and thermal stabilities 
of a series of synthesized cocrystal hydrates.  It was found that their stoichiometric 
compositions, crystal packing are unpredictable.  In addition, there was no correlation 
found between the crystal packing and thermal stability even when composition and 
structure are similar.  Database mining using the CSD of crystalline hydrates possessing 
the functional groups carboxylic acids and phenols revealed the unpredictability of 
supramolecular synthons exhibited by hydrates due to the versatility of the water 
molecule to engage in diverse hydrogen bonding interactions.   
Chapter 5 (Appendix 3) reports forms III and IV polymorphic forms of gallic acid 
monohydrate.  This is the first tetramorphic hydrate for which fractional coordinates have 
been determined.  An analysis of the hydrogen bonding patterns in these and other 
polymorphic hydrates suggests that waters of hydration are in general a nemesis to crystal 
engineers.   
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Chapter 2:  A Crystal Engineering Study of Gallic Acid and Ferulic Acid as 
Cocrystal Formers 
 
 
2.1 Introduction 
Crystal engineering
1
, the design of new molecular solids through invoking 
supramolecular chemistry, continues to invoke interest through the rapidly emerging 
fields of metal organic frameworks
2
, solid-state synthesis
3
 and pharmaceutical 
cocrystals.
4
   
The definition of a cocrystal is an active subject of discussion;
5
 we define it as “a 
stoichiometric multiple component crystal that is formed between two compounds that 
are solids under ambient conditions in which at least one cocrystal former is molecular 
and forms a supramolecular synthon with the remaining cocrystal former(s).”  Cocrystals6  
represent a long known but little studied class of compounds as they have been known 
since the 1840’s7 but even today they represent less than 0.5% of the structures that have 
been archived in the Cambridge Structural Database (CSD).
8
  Pharmaceutical cocrystals, 
cocrystals formed between active pharmaceutical ingredients (APIs) and a 
pharmaceutically acceptable cocrystal former have emerged into a new paradigm in 
pharmaceutical science as they afford new crystal forms of APIs without covalently 
modifying the API and they also create opportunities for intellectual property.
9
  Most 
importantly, they modify the physicochemical properties of the API such as stability,
10
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mechanical properties
11
 and solubility.
12
  As pharmaceutical cocrystals have become an 
inherent part of pharmaceutical solid form development, the selection of cocrystal former 
libraries remains a matter of debate.  Conventional wisdom suggests that 
pharmaceutically approved carboxylic acids and chemicals included in the generally 
regarded as safe (GRAS)
13
 and everything added to food in the United States (EAFUS) 
lists
14
  are, in effect, the cocrystal former library.  However, there are many other “safe” 
cocrystal formers that have the potential to serve as cocrystals formers as exemplified by 
nutraceuticals.
15
 
Nutraceuticals are naturally occurring compounds defined as “food, or parts of 
food, that provide medical or health benefits, including the prevention and/or treatment of 
diseases.” 16   They include dietary supplements, isolated natural substances and 
genetically-engineered designer foods, and are differentiated from pharmaceuticals by the 
claims, dosage and packaging of the product.
17
  Most nutraceuticals are derived from 
plants and exist as amino acids, carotenoids, vitamins and dietary polyphenols.  Dietary 
polyphenols, secondary plant metabolites, represent a wide variety of compounds that 
occur in fruits, vegetables, wine, tea, and cocoa products. They are mostly derivatives 
and/or isomers of flavonoids, stilbenes, catechins, and phenolic acids.  They exhibit many 
biologically significant functions, such as protection against oxidative stress and 
degenerative diseases, due to their antioxidant properties.
18
 Phenolic acids present in 
plants are hydroxylated derivatives of benzoic and cinnamic acids such as gallic acid and 
ferulic acid.
19
  They account for one third of the total intake of dietary polyphenols in the 
diet.  Ferulic acid, a hydroxycinnamic acid, is concentrated in the bran of grains, peel of 
fruits and roots and peels of vegetables.
20
  It is a bioactive agent that is found as the free 
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form or the conjugate form and has been approved as an additive antioxidant and food 
preservative in Japan.
21
  Gallic acid is found in the free form or esterified to catechins or 
proanthocyanidins.  It is widely used as antioxidant in the pharmaceutical industry 
because in vivo and in vitro studies have shown that it is cytotoxic against cancer cells,
22
 
possesses antibacterial and antifungal properties
23
 and has been found to be active against 
the viruses HIV-1 and HSV-1.
24
   
Phenolic acids are strong candidates to serve as cocrystal formers, because they 
possess multiple hydrogen bond donors and acceptors that are capable of forming a stable 
and diverse range of supramolecular synthons.   Furthermore, carboxylic acids and 
phenols are frequently encountered in APIs, pharmaceutical excipients and salt formers 
and can act as both hydrogen bond donors and hydrogen bond acceptors.  They are 
therefore self-complementary and can also engage in robust and reliable supramolecular 
heterosynthons with complementary functional groups as seen in the examples of 
supramolecular synthons composed of carboxylic acid dimers,
25
 amide dimers,
26
 
carboxylic acid-basic nitrogen,
27
 carboxylic acid-amides,
28
 phenol-basic nitrogen
29
 and 
phenol-carboxylates.
30
 An effective approach in the design of cocrystals is applying the 
supramolecular synthon approach, in particular exploiting reliable supramolecular 
synthons.   This approach involves an empirical analysis of the arrangement and 
frequency of occurrence of supramolecular synthons of a large number of crystal 
structures using the Cambridge Structural Database (CSD).
8
  A high probability of 
occurrence of a particular supramolecular synthon suggests a robust and reliable 
supramolecular synthon. 
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This paper addresses the use of gallic acid and ferulic acid, both of which are 
phenolic acids as cocrystal formers.  Eleven cocrystals of gallic acid and ferulic acid with 
cocrystal formers (Figure 2.1):  isoniazid (INZ), adenine (ADN), 3,5-dimethylpyrazole 
(DMP),  theobromine (TBR), urea (URE) and glycine anhydride (GAH) were isolated 
and structurally characterized.  
 
 
Figure 2.1. Cocrystal formers used herein, abbreviated as follows: INZ, ADN, DMP, 
TBR, URE, GAH. 
 
2.2 Materials and Methods 
2.2.1 Materials 
All reagents and solvents were purchased from commercial vendors and used without 
further purification.   
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2.2.2 Preparation of Cocrystals 
Gallic Acid.Isoniazid, GALINZ:  Gallic acid (17.0 mg, 0.100 mmol) and iso-nicotinic 
acid hydrazide (13.8 mg, 0.100 mmol) were dissolved in 2ml of methanol until a clear 
solution was obtained. The solution was left for slow evaporation at room temperature.  
Light brown prisms of GALINZ were obtained after 5 days. 
Gallic Acid.Dimethypyrazole, GALDMP:  Gallic acid (59.2 mg, 0.348 mmol) and 3,5-
dimethylpyrazole (35.4 mg, 0.368 mmol) were dissolved in 5ml of methanol until a clear 
solution was obtained. The solution was left for slow evaporation at 5
o
C.  Colorless 
prisms of GALDMP were obtained after 14 days. 
Gallic Acid.Adenine, GALADN:  Gallic acid (17.0 mg, 0.100 mmol) and adenine (13.7 
mg, 0.100 mmol) were dissolved in a 4 ml water/ethanol (1:3 ratio) and allowed to slowly 
evaporate at room temperature in a fume hood.  Colorless needles of GALADN were 
harvested after 3 days.   
Gallic Acid.Urea, GALURE:     Gallic acid (17.1 mg, 0.100 mmol) was dissolved in 1 
ml of ethanol.  The solution was added to 1 ml saturated solution of urea and allowed to 
slowly evaporate at room temperature in a fume hood.  Colorless needles of GALURE 
were harvested after 8 days.   
Gallic Acid.Glycine Anhydride, GALGAH:  Gallic acid (17.0 mg, 0.100 mmol) and 
glycine anhydride (12.0 mg, 0.105 mmol) were dissolved in 2ml of 50% aqueous acetone 
solution. The solution was left for slow evaporation at 5
o
C.  Colorless needles of 
GALGAH were obtained after a 7 days.  
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Ferulic Acid.Adenine, FERADN:  Ferulic Acid (19.4 mg, 0.100 mmol) and adenine 
(13.7 mg, 0.100 mmol) were dissolved in a 4 ml water/ethanol (1:3 ratio) and allowed to 
slowly evaporate at room temperature in a fume hood.  Colorless needles of FERADN 
were obtained after 9 days. 
Ferulic Acid.Isoniazid, FERINZ:  Ferulic acid (19.0 mg, 0.100 mmol) and 
isoniazid (13.7 mg, 0.100 mmol) were dissolved in 2ml of ethanol. The solution was left 
for slow evaporation at 5
o
C.  Colorless needles of FERINZ were obtained after a 3 days.  
Ferulic Acid.Dimethypyrazole, FERDMP:  Ferulic acid (19.4 mg, 0.100 mmol) and 
3,5-dimethylpyrazole 9.6 mg, 0.100 mmol) were dissolved in 5ml of methanol until a 
clear solution was obtained. The solution was left for slow evaporation at 5
o
C.  Yellow 
plates of FERDMP were obtained after 14 days. 
Ferulic Acid.Urea, FERURE:  Ferulic acid (19.2 mg, 0.100 mmol) was dissolved in 2 
ml of ethanol.  The solution was added to 1 ml saturated solution of urea and allowed to 
slowly evaporate at room temperature in a fume hood.  Colorless needles of FERURE 
were harvested after 8 days.   
Ferulic Acid.Glycine Anhydride, FERGAH:  Ferulic acid (19.0 mg, 0.1 mmol) and 
glycine anhydride (79.0 mg, 0.693 mmol) were dissolved in 2ml of 50% aqueous acetone 
solution. The solution was left for slow evaporation at 5
o
C.  Colorless needles of 
FERGAH were obtained after a 10 days.  
Ferulic Acid.Theobromine, FERTBR:  Ferulic acid (19.0 mg, 0.100 mmol) and 
theobromine (19.0 mg, 0.693 mmol) were dissolved in 4ml of 50% aqueous ethanol 
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solution. The solution was left for slow evaporation at room temperature.  Colorless 
needles of FERTBR were obtained after a 14 days.  
2.2.3 Methods 
Differential scanning calorimetry (DSC): Thermal analysis of the cocrystals was 
performed using a TA instrument DSC 2920 Differential Scanning Calorimeter.  
Hermetic aluminum pans were used for all samples and temperature calibrations were 
made using indium as a standard. The samples (1-3 mg) were scanned at a heating rate of 
10 °C/min from 30
o
C-350
o
C under a dry nitrogen atmosphere (flow rate 70ml/min). 
Thermogravimetric analysis (TGA): Thermogravimetric analysis was performed with a 
Perkin Elmer STA 6000 Simultaneous Thermal Analyzer. Open alumina crucibles were 
used for analysis in the temperature range 30°C to the appropriate temperature at 2-10 
°C/min scanning rate under nitrogen stream. 
Infrared spectroscopy (FT-IR): All crystalline samples were characterized by infrared 
spectroscopy using a Nicolet Avatar 320 FT-IR instrument. 2-3mg of material was used 
for all samples. Spectra were measured over the range of 4000 – 400cm-1 and data were 
analyzed using EZ Omnic software. 
Laboratory powder x-ray diffraction (PXRD): Bulk samples were analyzed by x-ray 
powder diffraction with a Bruker AXS D8 powder diffractometer using Cu Kα radiation 
(λ = 1.54056 Ǻ) and 40 kV; 30 mA.  Scanning interval of data was in the range of 3–40° 
2θ; time per step 0.5s. The experimental PXRD patterns and calculated PXRD patterns 
from single crystal structures were compared to confirm the composition of materials. 
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Single-crystal x-ray data collection and structure determinations: Suitable single 
crystals of GALURE, GALGAH, GALINZ, GALDMP, FERADN, FERURE, 
FERGAH and FERINZ were selected for single crystal x-ray crystallography.  Quality 
single crystals of FERDMP and GALADN could not be obtained but the crystal 
structure of GALADN was solved from the synchrotron powder X-ray diffraction pattern 
as described below.  The validity of structure solution of cocrystals from powder x-ray 
diffraction pattern has been well established, although structures from powder data 
generally have less precision in atomic positions than those from single crystal data.
31
  
The diffraction data for single crystals of GALDMP was collected on a Bruker-AXS 
SMART APEX CCD diffractometer with monochromatized Mo Kα radiation ((λ = 
0.71073 Å), whereas data for single crystals of the hydrates of GALURE, GALGAH, 
GALINZ, FERADN, FERURE, FERGAH and FERINZ were collected on a Bruker-
AXS SMART APEX 2 CCD diffractometer with monochromatized Cu Kα radiation (λ = 
1.54178 Å). Diffractometers were equipped with KRYO-FLEX low temperature device 
and diffraction experiments were carried out at 100K.  Indexing was performed using 
SMART v5.625 
32
 or using APEX 2008v1-0. 
33
  Frames were integrated with SaintPlus 
7.51
34
 software package.  Structures were solved by direct methods and refined by full 
matrix least-squares based on F2 using the SHELXTL package.
35
  Absorption correction 
was performed by a multiscan method implemented in SADABS.
36
  All non-hydrogen 
atoms were refined anisotropically.  Hydrogen bonds were solved as follows: 
GALINZ: Hydrogen atoms of NH2 groups were located from difference Fourier map and 
freely refined except H7 for which Uiso(H) = 1.2Ueq(-NH). 
All the other hydrogen atoms were placed geometrically and refined using riding model 
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with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) = 1.2Ueq(-
CH,-NH). 
GALDMP: Hydrogen atoms of -OH and =NH groups were located from the difference 
Fourier map and refined freely or freely with thermal parameters: Uiso(H) = 1.5Ueq(-
OH) for H231 and H271. Hydrogen H271 was refined using distance restraints (free 
refinement resulted in 1.055A O-H distance). All the other hydrogen atoms were placed 
geometrically and refined using riding model with isotropic thermal parameters Uiso(H) 
= 1.2Ueq(-CH), Uiso(H) = 1.5Ueq(-CH3). 
GALURE: Hydrogen atoms of NH2 groups were located from difference Fourier map 
and freely refined with isotropic thermal parameters. All the other hydrogen atoms were 
placed geometrically and refined using riding model with isotropic thermal parameters 
Uiso(H) = 1.5Ueq(-OH), Uiso(H) = 1.2Ueq(-CH).  
GALGAH: Hydrogen atoms of NH groups were located from difference Fourier map 
and freely refined with isotropic thermal parameters. All the other hydrogen atoms were 
placed geometrically and refined using riding model with isotropic thermal parameters 
Uiso(H) = 1.5Ueq(-OH), Uiso(H) = 1.2Ueq(-CH2,-CH).  
FERADN: Hydrogen atoms of NH2 group were located from difference Fourier map and 
refined using distance restraints with isotropic thermal parameters (Uiso(H) = 1.5Ueq(-
NH2). 
All the other hydrogen atoms were placed geometrically and refined using riding model 
with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) = 1.2Ueq(-
CH,-NH). 
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FERINZ: Hydrogen atoms of NH2 group were located from difference Fourier map and 
refined using distance restraints with isotropic thermal parameters (Uiso(H) = 1.5Ueq(-
NH2). All the other hydrogen atoms were placed geometrically and refined using riding 
model with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) = 
1.2Ueq(-CH,-NH). 
FERURE: Hydrogen atoms of -OH groups were located from the difference Fourier map 
and freely refined. All the other hydrogen atoms were placed geometrically and refined 
using riding model with isotropic thermal parameters Uiso(H) = 1.2Ueq(-CH,-CH2,-NH), 
Uiso(H) = 1.5Ueq(-CH3, -OH). 
FERGAH: All hydrogen atoms were placed geometrically and refined using riding 
model with isotropic thermal parameters Uiso(H) = 1.2Ueq(-CH,-NH2), Uiso(H) = 
1.5Ueq(-CH3,-OH). 
Crystallographic data are presented in Table 2.1.  Hydrogen bond parameters are given in 
Table 2.2. 
Synchrotron powder x-ray data collection and structure determinations: A high 
resolution synchrotron X-ray powder diffraction pattern was collected at the X16C 
beamline at the National Synchrotron Light Source at Brookhaven National Laboratory. 
X-rays of wavelength 0.700154 Å were selected using a Si(111) channel cut 
monochromator. After the sample, the diffracted beam was analyzed with a Ge(111) 
crystal and detected by a NaI scintillation counter. Wavelength and diffractometer zero 
were calibrated using a sample of NIST Standard Reference Material 1976, a sintered 
plate of Al2O3. Samples were flame-sealed in thin walled glass capillaries of nominal 
44 
 
diameter 1.5 mm and spun during data collection for improved powder averaging.  This 
measurement was performed at ambient temperature, nominally 295 K. 
 
 
Figure 2.2: High-resolution synchrotron powder diffraction data (dots) and Rietveld fit 
of the data for GALADN. The lower trace is the difference, measured minus calculated, 
plotted to the same vertical scale 
 
TOPAS-Academic
37,38,39
 was used to index, solve, and refine the crystal structure 
of GALADN. From systematic absences in the pattern, a space group of P21/c was 
hypothesized.  Structure solution was performed by simulated annealing, with each 
molecule being defined as a rigid body on a general position. From this preliminary 
solution, Rietveld refinement was successfully performed (Figure 2.2). Both of the 
molecules were defined as rigid bodies, with similar bonds and angles (aromatic bonds, 
C-C single bonds, e.g.) refined jointly to a single value.  The powder diffraction data set 
does not contain sufficient information to give reliable hydrogen atom positions. 
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 GALINZ GALDMP GALADN GALURE GALGAH 
Formula 
C13H13N3O
6 
C17H22N4O5 C12H11N5O5 C8H10N2O6 C11H12N2O7 
MW 307.26 362.39 305.25 230.18 284.23 
Crystal 
system 
Triclinic Triclinic Monoclinic Monoclinic Triclinic 
Space group P-1 P-1 P21/c P21/c P-1 
a  (Å) 8.6337(3) 8.074(2) 7.96634(14) 9.7502(3) 6.0418(2) 
b (Å) 11.9056(5) 8.149(2) 6.33221(23) 9.8774(3) 7.9997(2) 
c (Å) 13.3621(5) 15.091(4) 24.8483(4) 10.2927(3) 13.0244(3) 
α (deg) 94.353(2) 95.811(5) 90 90 103.309(2) 
β (deg) 99.401(2) 93.004(5) 96.2093(16) 109.204(2) 91.082(2) 
γ (deg) 108.929(2) 117.408(4) 90 90 109.7880(10) 
V / A
3
 1269.47(8) 871.4(4) 1246.11(4) 936.09(5) 573.19(3) 
Dc/g cm
-3
 1.608 1.381 1.589 1.633 1.647 
Z 4 2 4 4 2 
2θ range 
3.38 to 
65.97 
2.73 to 25.03 3 to 40 4.80 to 67.95 3.51 to 66.04 
Nref./Npara 4165/420 3031/265 - 1677/166 1914/196 
T /K 100(2) 100(2) 300 100(2) 100(2) 
R1 [I>2σ (I)] 0.0444 0.0406 - 0.0323 0.0369 
wR2 0.1130 0.1060 - 0.0853 0.0925 
Rwp
a
 - - 0.0725 - - 
Rexp
b
 - - 0.0476 - - 
GOF 0.999 1.039 1.523 1.084 1.095 
Abs coef 1.109 0.103 0.123 1.237 1.211 
 FERINZ FERADN FERURE FERGAH FERTBR 
Formula 
C16H17N3O
5 
C15H15N5O4 C14H18N4O6 C14H16N2O6 C17H20N4O7 
MW 331.33 329.32 314.30 308.29 392.37 
Crystal 
system 
Monoclinic Orthorhombic Monoclinic Monoclinic Monoclinic 
Space group P21/c Pca21 P21/c Pc C2/c 
a  (Å) 13.681(4) 13.2739(4) 19.950(1) 10.9682(3) 30.546(4) 
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b (Å) 3.798(12) 16.2621(5) 10.2970(5) 12.7359(3) 6.8895(9) 
c (Å) 29.843(10) 6.9427(3) 7.2349(4) 10.2315(3) 17.209(2) 
α (deg) 90 90 90 90 90 
β (deg) 101.914(5) 90 94.914(3) 97.599(2) 93.725(6) 
γ (deg) 90 90 90 90 90 
V / A
3
 1517(5) 1498.66(9) 1480.77(13) 1416.69(7) 3619.9(8) 
Dc/g cm
-3
 1.451 1.460 1.410 1.445 1.442 
Z 4 4 4 4 8 
2θ range 
3.30 to 
44.48 
2.72 to 67.07 
2.22 to 
65.82 
3.47 to 65.98 2.90 to 52.63 
Nref./Npara 1206/229 2421/226 2497/208 4124/403 2042/259 
T /K 293(2) 100(2) 100(2) 225(2) 298(2) 
R1 [I>2σ (I)] 0.0762 0.0354 0.0445 0.0537 0.0742 
wR2 0.1734 0.0827 0.1062 0.1413 0.1965 
Rwp
a
 - - - - - 
Rexp
b
 - - - - - 
GOF 0.994 1.065 1.081 1.004 1.016 
Abs coef 0.920 0.918 0.974 0.971 0.965 
 
Table 2.1: Crystallographic data and structure refinement parameters for the cocrystals 
presented herein. 
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 Hydrogen bond d (H · · · A) 
/Å 
D (D · · · A)/Å <(DHA) 
GALINZ N-HO 2.20 2.942(2) 142.2 
N-HO 2.56(3) 3.427(3) 169(2) 
N-HO 2.24 2.913(2) 132.8 
N-HO 2.18(3) 3.044(3) 162(2) 
O-HO 2.07 2.802(2) 145.3 
O-HO 2.04 2.755(2) 142.8 
O-HN 1.80 2.636(2) 174.8 
O-HN 1.89 2.717(2) 167.6 
O-HN 1.84 2.675(2) 173.9 
O-HN 1.87 2.699(2) 167.6 
GALDMP N-HO 2.14(2) 2.9314(19) 151.7(17) 
N-HO 1.95(2)      2.8092(19) 162(2) 
O-HN 1.67(3)      2.6190(18) 167(2) 
O-HN 2.51(2)      3.3135(19) 140.6(18) 
O-HO 1.97(2)      2.7410(16)   144.9(19) 
O-HO 2.27(2)      2.7283(16) 112.0(17) 
O-HO 1.84(3)      2.6800(17) 160(2) 
O-HN 1.658(18)   2.5891(17) 169(3) 
GALURE 
O-HO 1.73 2.5282(14)   158.5 
O-HO 1.89           2.7012(14) 162.4 
O-HO 2.04          2.8346(14) 156.5 
O-HO 2.10         2.8263(14)   144.7 
N-HO 2.37(2)         3.2347(17)   159.9(16) 
N-HO 2.542(19) 3.0048(17)  112.2(15) 
N-HO 2.31(2) 2.8264(17) 120.0(16) 
N-HO 2.12(2) 2.9961(18) 168.5(18) 
GALGAH O-HO 1.80    2.6382(14) 178.6 
O-HO 2.06         2.7229(15)   135.2 
O-HO 1.91 2.7480(15) 175.7 
O-HO 1.78         2.6102(15) 169.1 
N-HO 1.94(2) 2.8537(17)   165.7(18) 
N-HO 2.08(2) 2.9349(17) 166.7(19) 
FERINZ O-HO 2.19         2.647(8)     115.8 
O-HO 2.37         3.000(8)     134.4 
O-HN 1.82         2.634(9)     174.6 
N-HO 2.06(2)      2.91(1)      176(8) 
N-HO 2.32(4)      3.17(1)      159(8) 
N-HO 2.25(7)      2.96(1)      137(8) 
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FERADN O-HN 1.98         2.715(2)     146 
N-HN 2.00             2.826(2) 155 
N-HO 2.09(2)      2.964(3)     164(2) 
FERURE 
 
O-HO 1.75(3) 2.639(2) 168(3) 
N-HO 2.14         2.983(3)     160.7 
N-HO 2.32         3.023(2)     136.4 
N-HO 2.41         3.108(2)     137.0 
N-HO 2.08         2.951(3)     168.5 
N-HO 2.25         2.986(2)     141.2 
N-HO 2.06         2.936(2)     172.1 
N-HO 2.07         2.945(2)     174.2 
N-HO 2.29         3.079(2)     150.0 
O-HO 1.72(4)      2.616(2)      
FERGAH O-HO 2.02    2.677(5) 135.1 
O-HO 2.01 2.646(4) 132.5 
N-HO 2.58         3.157(5)     124.5 
N-HO 2.25         3.097(5)     164.1 
FERTBR.H2O O-HO 1.79         2.600(7)     167.4 
O-HO 1.89         2.710(7)     175.5 
N-HO 2.00         2.858(7)     172.5 
O-H(W)O 2.09(5)      2.865(7)     150(7) 
O-H(W)O 1.90(3)      2.764(7)     169(9) 
 
Table 2.2:  Selected hydrogen bond distances and parameters of cocrystals 
 
 
Supramolecular Synthon Carboxylic acids and 
Primary Amides 
Carboxylic acids and 
Secondary amides 
Raw 
(254 
entries) 
Refined 
(38 entries) 
Raw 
(1141 
entries) 
Refined 
(184 entries) 
COOH
…
CONH 124 
(48.8%) 
32 (84.2%) 78 (6.8%) 7 (3.8%) 
COOH
…
COOH 15 (5.9%) 3 (7.9%) 123 (10.8%) 40 (21.7%) 
CONH
…
CONH 87 (34.3%) 4 (10.5%) 117 (10.3%) 36 (19.6%) 
 
Table 2.3:  Comparison of Supramolecular Homosynthon versus Supramolecular 
Heterosynthon of Carboxylic acids with Primary and Secondary Amides 
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2.3 Results 
GALINZ:  GAL and INZ form a cocrystal that crystallizes in the space group P-1 with 
two independent molecules of GAL and two independent molecules of INZ in the 
asymmetric unit.  The crystal structure reveals the existence of hydrogen bonded 
interactions between the two symmetrically independent GAL molecules via phenolic 
supramolecular homosynthons (O
…
O: 2.757(1), O
…
O: 2.805 (1)Å). The phenolic 
homodimers of GAL act as H-bond donors and acceptors to the hydrazide moieties of the 
two symmetrically independent molecules of INZ via R
3
3(7) ring motifs so as to form 
four component supramolecular assemblies of GAL and INZ molecules.    This four 
component supramolecular assembly in turn forms H-bonded tapes that are sustained by 
COOH
…
Nbasic supramolecular heterosynthons (O
…
N:  2.636(3) Å), thereby forming a two 
dimensional network (Fig. 2.3a).  The carbonyl moiety of one symmetrically independent 
GAL molecule hydrogen bonds with the amine moiety of INZ (N
…
O:  3.044(1) Å) to 
form bilayers that are connected by π interactions (Fig. 2.3b). 
(a)  
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(b)  
Fig 2.3:  (a) Crystal packing in GALINZ reveals form H-bonded tapes that are sustained 
by COOH
…
Nbasic supramolecular heterosynthons (b) Illustration of bilayers of GALINZ 
sheets. 
 
GALDMP:  GALDMP is a 1:2 cocrystal that crystallizes in space group P-1 with one 
molecule of GAL and two molecules of DMP in the asymmetric unit. The crystal 
structure of GALDMP reveals that GAL molecules form phenolic supramolecular 
homosynthons (O
…
O:  2.741(7) Å) that self-assemble to form tapes along the b axis.  The 
homodimers further hydrogen bond to crystallographically independent DMP molecules 
via an R
3
3(7) ring motif (Fig. 2.4a).  The third hydroxyl moiety of the gallic acid 
molecule interacts with the basic nitrogen of the second crystallographically independent 
DMP molecule and the phenolic moiety of a GAL molecule to generate a trimeric ring 
motif, R
3
3(9) (Fig. 2.4b). The crystal packing is a two dimensional network (Fig. 2.4c). 
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      (a)         (b)  
(c)  
Fig. 2.4:  (a) Phenolic homodimers of GAL molecules acts as a donor and an acceptor to 
DMP molecules (b) R
3
3(9) trimeric motif involving two GAL molecules and a DMP 
molecule (c) Crystal packing in GALDMP reveals a 2D network of GAL and DMP 
molecules. 
 
GALADN:   The crystal structure of GALADN reveals the self-assembly of GAL and 
ADN molecules in the monoclinic space group P21/c.  The carboxylic acid moieties of 
GAL molecules and the aminopyridine moieties of ADN molecules form R
2
2(8) 
52 
 
supramolecular heterosynthons (N
…
O:  2.880(17) Å; O
…
O:  2.644(78) Å) to generate 
chains.  These chains are interconnected through the formation of phenolic homodimers 
of GAL molecules (O…O:  2.701(11) Å, Fig. 2.5).  In addition, the exterior H-bond 
donor and acceptor sites of the phenolic homodimers are exploited by ADN molecules of 
adjacent chains to generate a 3D network.  
 
 
Fig 2.5:  Crystal packing in GALADN reveals form H-bonded interactions between the 
carboxylic acid moiety of GAL molecules and the aminopyridine moiety of ADN 
molecules. 
 
GALURE:  GAL and URE molecules crystallize in the monoclinic space group P21/c 
with one molecule of each in the asymmetric unit.  The crystal structure reveals that GAL 
and URE molecules form carboxylic acid-amide supramolecular heterosynthons (O
…
O 
2.528(1)Å, N
…
O:  2.996(1) Å).  These heterodimers are cross linked by NH
…
OH 
hydrogen bonds (N
…
O:  3.005(1) Å) to form tapes.  The heterodimers are linked 
perpendicularly to adjacent tapes by accepting a hydrogen bond from the amine and 
phenolic moieties (O
…
O:  2.701(1) Å; N
…
O:  2.826(1) Å).   Additionally, the phenolic 
moiety of the GAL molecule from the adjacent tape accepts a bifurcated hydrogen bond 
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from the phenolic moiety of the GAL molecule and the amine moiety of the URE 
molecule (O
…
O:  2.835(1) Å; N
…
O:  2.984(1) Å, Fig. 2.6). 
 
Fig. 2.6:  Crystal packing in GALURE reveals molecular tapes of heterodimers of GAL 
and URE molecules. 
 
GALGAH:  The crystal structure of GALGAH contains two independent molecules of 
GAH molecules and one independent molecule of GAL in the unit cell.  The GAL 
molecules form undulating chains sustained by carboxylic acid supramolecular 
homosynthons (O
…
O: 2.610(1) Å) and phenolic supramolecular homosynthons (O
…
O: 
2.723(1) Å).  This undulating chain of homodimers is absent in both the anhydrous and 
hydrated forms of GAL.  An independent GAH molecule acts as both a hydrogen bond 
donor and acceptor towards the phenolic homodimers by forming a tetrameric motif 
(NH
…
OH:  2.935(1) Å, OH
…
O:  2.635(1) Å,) to connect each chain, thereby forming a 
sheet (Fig. 2.7a).  The other GAH molecule interacts with the GAL chains via OH
…
O 
hydrogen bonds (O
…
O: 2.748(1) Å) and further connect the sheets above and below 
through amide-amide supramolecular homosynthons (N
…
O:  2.854(1) Å, Fig. 2.7b).   
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   (a)  
(b)  
Fig. 2.7:  (a) Crystal packing in GALGAH reveals undulating tapes sustained by dimers 
of GAL molecules linked by GAH molecules to form sheets (b) Illustration of sheets 
interconnected by homodimers of GAH molecules. 
 
FERADN:  The crystal structure of FERADN reveals that FER and ADN molecules in 
the unit cell.   FER and ADN molecules form two point supramolecular heterosynthons 
between the acid moiety of FER and the amine and basic nitrogen of the ADN molecule 
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to form 1-D chains (NH
…
O:  2.839 (1)Å; OH
…
O:  2.692(1) Å, Fig. 2.8a).  Adjacent 
chains are cross linked by hydrogen bonding interactions between one FER molecule and 
two ADN molecules via R
3
3(10) motifs to result in an interpenetrated three dimensional 
network (Fig. 2.8b). 
  (a)  
  (b)  
Fig. 2.8:  (a) Crystal packing in FERADN reveals two point recognition supramolecular 
heterosynthons between the acid moiety of FER molecule and the amine and the basic 
nitrogen moiety of the ADN molecule (b) Crystal packing of FERADN is that of a 3D 
interpenetrated network. 
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FERINZ:  FER and INZ crystallize in space group P-1 with two molecules of each 
component in the asymmetric unit.  The crystal structure of FERINZ is sustained by the 
robust COOH
…
Nbasic supramolecular heterosynthons (O
…
N:  2.636(5) Å, Fig. 7a).  The 
INZ molecules interact via NH
…
O (N
…
O:  2.968(7) Å) supramolecular homosynthons to 
form R
2
2(10) dimers (Fig. 2.9a).  The intermolecular H-bonding generates a herring bone 
pattern as presented in Fig. 2.9b.   
   (a)  
         (b) 
Fig. 2.9:  (a) Crystal packing in FERINZ sustained by COOH
…
Nbasic supramolecular 
heterosynthons (b) Herring bone pattern of FERINZ. 
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FERURE:  FER and URE molecules form a 1:2 adduct that crystallizes in the 
monoclinic space group P21/c.   Both independent URE molecules form amide-amide 
supramolecular homosynthons that generate tapes along the b axis.  The NH
…
O bond 
distances are 2.945(3)Å and 2.936(3)Å for the first independent URE molecule and 
2.982(3)Å and 2.951(3)Å for the second independent URE molecule.  The homodimers 
are further interconnected through a two point hydrogen bond between the amine 
moieties of URE and the hydroxyl and methoxyl moieties of FER ((N
…
O:  2.986(2)Å, 
N
…
O:  3.023(2)Å, Fig. 4a) at a dihedral angle of 77.33
o
.  In addition, the carbonyl moiety 
of the URE molecule accepts a hydrogen bond from the carboxylic acid moiety of FER 
(Fig. 2.10).   
 
Fig. 2.10:  Crystal packing in FERURE reveals amide-amide supramolecular 
homosynthons between URE molecules to generate tapes that are interconnected by FER 
molecules. 
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FERGAH:  The 2:2 cocrystal of FER and GAH is sustained by chains of GAH 
molecules via amide-amide supramolecular homosynthons (N
…
O:  2.987(1) Å; N
…
O:  
2.225(1) Å).  The chains of GAH molecules are interconnected by FER molecules 
through OH
…
O hydrogen bonding (O
…
O:  2.615(1)Å) resulting in the formation of a 
sheet as illustrated in Fig. 2.11. 
 
Fig. 2.11:  Crystal packing in FERGAH reveals molecular tapes of amide-amide 
supramolecular homosynthons between GAH molecules interconnected by FER 
molecules. 
 
FERTBR: The crystal structure of FERTBR 
. 
H2O reveals a 1:1 cocrystal monohydrate 
which crystallizes in the monoclinic space group C2/c.  The crystal structure consists of 
FER and TBR molecules that form acid-imide supramolecular heterosynthons (N
…
O:  
2.858(3) Å, O
…
O:  2.602(3) Å) interconnected by water molecules to form discrete 6-
component supramolecular assemblies (Fig 2.12).   
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Fig 2.12:  Crystal packing of FERTBR 
. 
H2O reveals that FERTBR heterodimers are 
connected by water molecules. 
 
 
2.4 Discussion 
  Six cocrystal formers were studied herein and they afforded five pairs of 
cocrystals of gallic acid and ferulic acid (INZ, ADN, DMP, URE and GAH).  The 
eleventh FERTBR.H2O can also be paired since the crystal structure of gallic acid and 
theobromine dihydrate has been reported elsewhere.
40
 The data presented herein shows 
that phenolic acids can generally be considered as reliable cocrystal formers with 
molecules that contain a basic nitrogen/amide moiety.  A CSD survey of phenolic acids 
(i.e. hydroxylated derivatives of benzoic acids and cinnamic acids) resulted in 324 
entries, of which 159 are cocrystals.  However, the number of entries of gallic acid and 
ferulic acid cocrystals are 8 and 5 entries respectively.   
The reliability of the supramolecular synthon approach as a design tool for the 
preparation of cocrystals has been systematically explored in several studies.
25,27, 41
  
Carboxylic acids are known to form persistent supramolecular heterosynthons with 
60 
 
weakly basic nitrogen or amide moieties.  Studies have also focused upon weakly acidic 
OH groups and their ability to form supramolecular heterosynthons with basic nitrogen 
and carboxylate moieties have been established.  For example, it has been reported that 
the probability of occurrence of COOH
…
Nbasic in the presence and absence of competing 
functional moieties are 77% and 97%, respectively.
25  
The cocrystals reported herein 
focus upon the hierarchy of supramolecular synthons when phenolic and carboxylic acid 
moieties are present in the same molecule.  GALADN, GALDMP, GALINZ, FERINZ 
and FERADN all exhibit the carboxylic acid-basic nitrogen supramolecular 
heterosynthon.   The COOH
…
Nbasic bond distance range is 2.588(4) to 2.692(1) Å and 
reveals the robustness of the COOH
…
Nbasic supramolecular heterosynthon.  The bond 
distance range of carboxylic acid aromatic nitrogen supramolecular heterosynthon ranges 
from 2.5 to 3.0 with a mean distance of 2.652(2).  However, in FERTBR.H2O, the 
COOH
…
Nbasic supramolecular heterosynthon is absent and is replaced by the acid-imide 
supramolecular heterosynthon.  This anomaly may be attributed to the presence of the 
water molecule.  Indeed, a CSD survey of TBR cocrystals with carboxylic acids reveals 
five entries:  CSATBR, HIJYAB, HIJYEF, NURYUV and MUPPET.  HIJYAB and 
NURYUV formed the COOH
…
Nbasic supramolecular heterosynthon and the TBR 
molecules formed the imide homodimers.  Similarly, crystal structures of CSATBR and 
HIJYEF are sustained by the COOH
…
Nbasic supramolecular heterosynthon and also form 
the acid-imide supramolecular heterosynthon due to the presence of a second carboxylic 
acid moiety.  In contrast, MUPPET, a cocrystal consisting of gallic acid, theobromine 
and two water molecules, did not form the COOH
…
Nbasic supramolecular heterosynthon, 
instead water molecules are hydrogen bonded to the imidazoyl moiety and the acid-imide 
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supramolecular heterosynthon is formed.  In both FERTBR.H2O and GALTBR.2H2O, a 
six component supramolecular assembly between two FER or GAL molecules, two TBR 
molecules and water molecule(s) is observed.   Indeed, it has been asserted that, although 
carboxylic acids and phenols form supramolecular synthons with aromatic nitrogen even 
in the presence of competing functional groups, the supramolecular synthons exhibited 
between carboxylic acids, phenols and water molecules are rather diverse.
34
   
Furthermore, the promiscuity of waters of hydration in terms of the supramolecular 
heterosynthons they exhibit is exemplified by the four polymorphs of gallic acid 
monohydrate.
42
   
GALURE exhibits the acid-amide supramolecular heterosynthon but it is absent 
in FERURE, FERGAH and GALGAH.   FERGAH and FERURE both exhibit infinite 
chains of self-complementary amide-amide supramolecular homosynthons.  GALGAH 
consists of two independent GAH molecules, one of which retained the amide-amide 
supramolecular homosynthons whereas the other hydrogen bonds to the phenolic 
homosynthons.  Infantes et al, studied the probability of hydrogen bonding interactions of 
various functional groups and it was demonstrated that the relative strength of 
supramolecular homosynthons is in the order of:  amides > acids > alcohols functional 
groups.
43
  However, several studies show that in the presence of carboxylic acids, there is 
84% probability of the occurrence of the acid-primary amide supramolecular 
heterosynthon.
24,25
  Indeed, a recent study concerning the hydrogen bonding binding 
energy between primary amides vs that between acid and primary amides indicated that 
the acid-amide interaction is stronger than the amide-amide interaction.
44
 These studies 
concentrated on primary amides and the question arises if this also holds true for 
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secondary amides.  A CSD analysis of the occurrence of the acid-secondary amide 
supramolecular heterosynthon indicates 3.8% occurrence in the absence of competing 
functional groups (Table 3).  Further analysis reveals that the acid supramolecular 
homosynthon and the amide supramolecular homosynthon occur 21.7% and 19.6%, 
respectively.   
The phenolic supramolecular homosynthon is observed in cocrystals of 
GALADN, GALINZ, GALDMP and GALGAH.  A CSD survey reveals that out of 466 
entries of organic molecules with a catechol functional moiety, 94 (20.1%) form phenolic 
homodimers.  Elimination of competing functional moieties resulted in 13 entries, and 8 
(61.5%) formed phenolic homodimers.  The rule of thumb in hydrogen bonding 
according to Etter is that hydrogen bonds form in a hierarchical fashion whereby the best 
hydrogen bond donor and acceptor preferentially interact with each other, followed by 
the second best hydrogen bond donor and acceptor, etc.
45
  Indeed, the crystal structures of 
GALADN, GALDMP and GALINZ are consistent with Etter’s rule since the phenolic 
homodimers are presumably a consequence of the formation of the robust COOH
…
Nbasic 
supramolecular heterosynthon.   
 
2.5 Conclusion 
In summary, this work has demonstrated the use of gallic acid and ferulic acid as 
reliable cocrystal formers with molecules containing a basic nitrogen/amide moiety.  Of 
the six cocrystal formers studied; five pairs of cocrystals of gallic acid and ferulic acid 
with INZ, ADN, DMP, URE and GAH were afforded.  FERTBR.H2O can also be 
paired since GALTBR.2H2O was previously reported.  The crystal structures of the 
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anhydrous cocrystals reveal the hierarchy of the COOH
…
Nbasic supramolecular 
heterosynthon in the presence of phenolic moieties.  However, FERTBR.H2O illustrates 
the challenges that may arise when a water molecule is incorporated in the crystal lattice 
since crystalline hydrates are capricious in terms of the supramolecular heterosynthon 
they exhibit. 
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Chapter 3:  Crystal Engineering of Isostructural Quaternary Multi-Component 
Crystal Forms of Olanzapine. 
 
3.1 Introduction 
Crystal engineering,
1,2
 has matured into a well-recognized aspect of solid-state 
chemistry research and is focused on the design of novel crystalline solids with tunable 
physicochemical properties.  The selection of a suitable crystal form of an active 
pharmaceutical ingredient (API) is particularly relevant to oral drug delivery,
 3
 and it 
profoundly influences the development and performance of the API.  Crystal forms of 
APIs have spanned polymorphs,
4
 solvates,
5
 hydrates
6
 and more recently, pharmaceutical 
cocrystals.
7,8
 
Pharmaceutical cocrystals can be defined as multiple component crystals in which 
at least one component is molecular and a solid at room temperature (the cocrystal 
former) and forms a supramolecular synthon with a molecular or ionic API.  
Pharmaceutical cocrystals have emerged as a new paradigm in pharmaceutical solid form 
development to diversify the range of crystal forms exhibited by APIs, allowing 
opportunities for improved performance characteristics and extend the product life and 
patent coverage of the API.
9
,
10
  Most importantly, pharmaceutical cocrystals can enhance 
physicochemical properties of APIs such as solubility,
11
 stability
12
 and mechanical 
properties
13
 while preserving the intended intrinsic activity of the API.  In addition, 
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pharmaceutical cocrystals have been incorporated with other techniques used to modulate 
physicochemical properties as noted in the examples of nanocrystalline cocrystals
14
 and 
cocrystals of salts.
15
   
Pharmaceutical cocrystals are amenable to design due to the ubiquitous nature of 
APIs, in that, they possess exterior functional groups that readily engage in 
supramolecular synthons with a wide variety of pharmaceutically acceptable cocrystal 
formers.  However, this semi-empirical approach becomes challenging for APIs that 
exhibit conformational flexibility and/or possess multiple functional groups.
16
 In 
addition, the design or engineering of compositions with more than two unique 
components becomes challenging due to the functional diversity introduced by each 
component.   
Olanzapine (2-methyl-4-(4-methyl-l-piperazinyl)-10H-thieno-[2,3b][1,5]benzo-
diazepine), a BCS
17
 class II (low solubility, high permeability) API was selected as a 
crystal engineering candidate.  Olanzapine is a widely prescribed atypical antipsychotic 
drug marketed under the trademark name Zyprexa
®
 by Eli Lilly and Company.  The drug 
is therapeutically effective in treating psychiatric disorders such as schizophrenia and 
manic episodes associated with bipolar disorder.
18
  Olanzapine has been shown to be 
effective in the reduction of not only positive symptoms (hallucinations and delusions), 
but also negative and cognitive symptoms (social and emotional withdrawal) in acute and 
relapsing schizophrenics.
19
  Crystal forms of olanzapine are well-documented and include 
six anhydrous polymorphs,
20,21 ,22 ,23
 three polymorphic dihydrates,
24
 two polymorphic 
sesquihydrates, several solvated forms,
25
 mixed solvates and hydrates,
26
 salts and an 
amorphous form.
27
   Much research has been done to develop novel crystal forms of 
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olanzapine.  Reutzel-Edens et al discussed the polymorphism of olanzapine dihydrate and 
the structural relationship between the anhydrates and hydrates.
28
  Nangia et al showed 
that the solubility of olanzapinium monomaleate and dimaleate salts was 225-550 times 
greater than that of free base olanzapine.
29
   
Isostructural cocrystals, i.e. crystal forms that exhibit the same or similar crystal 
structure,
30
 have been reported in the literature.
31
  These crystal forms, primarily binary 
cocrystals, are generally designed by interchanging structurally equivalent functional 
groups such as chloride/methyl exchange, Br/I or CH/N.
 32
  The design and successful 
synthesis of isostructural olanzapine cocrystals is remarkable in the context that it 
contains four distinct molecular entities.  Indeed, it has been shown recently that the 
subtle changes in the chemical composition of the API, i.e. swapping the sodium for the 
potassium cation, can result in significant and unpredictable changes in both the packing 
arrangement and physicochemical properties of the salt of the API.
33
  The design of 
isostructural cocrystals based on the analysis of the existing crystal forms offers unique 
opportunities to systematically fine-tune the physicochemical properties of the API by 
controlling the molecular arrangement in the solid state.  This article illustrates a design 
strategy to construct multi-component crystal forms of olanzapine a priori from the 
systematic analysis of existing crystal structures, culminating in the formation of multi-
component compositions with four unique molecules. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Olanzapine was obtained from Alkermes Inc. and used without further purification.  
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Cocrystal formers were purchased from commercial vendors and used without further 
purification (Figure 3.1).  Solvents purchased from commercial vendors were distilled 
before use.  All cocrystals were analyzed by powder X-ray diffraction (PXRD), and 
single crystal X-ray analysis where applicable.  
 
 
Figure 3.1:  Chemical structures of olanzapine and cocrystal formers used herein. 
 
3.2.2 Preparation of Cocrystals 
Olanzapine ·Nicotinamide Isopropyl acetate Tetrahydrate, OLANAM.IPA.4H2O:  
Olanzapine (40 µL of a 25mg/ml stock solution) and nicotinamide (37.6 µL of a 20 
mg/mL stock solution) were added to a glass vial and the solvent was dried under 
nitrogen flow.  Isopropyl acetate was added to the mixture and the sealed vial was heated 
at 70 
o
C for two hours.  The solution was then cooled at 5 
o
C for 24 hours.  The solution 
was concentrated to 50 µL total volume, recapped and left at 5 
o
C for an additional 24 
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hours.  Large yellow plates of the OLANAM.IPA.H2O were collected and allowed to 
dry at ambient conditions. 
Olanzapine ·Salicylamide Isopropyl acetate Tetrahydrate OLASAM.IPA.H2O:  
Olanzapine (7.5 mg, 0.024 mmol) and salicylamide (5.1 mg, 0.037 mmol) were dissolved 
in 1 mL isopropyl acetate and heated at 90 
o
C until all the solid material was dissolved.  
The vial was sealed and the solution was allowed to slowly evaporate at 5 
o
C.  After three 
days, large yellow plates of the OLASAM.IPA.H2O were collected by gravimetric 
filtration and dried at room temperature.  
Olanzapine ·p-Hydroxybenzamide Isopropyl acetate Tetrahydrate, 
OLAPHBNZ.IPA.4H2O:  Olanzapine (7.5 mg, 0.024 mmol) and p hydroxybenzamide 
(7.0 mg, 0.051 mmol) were dissolved 1 mL isopropyl acetate and heated at 90 
o
C until all 
the solid material was dissolved.  The sealed vial was sealed was allowed to slowly 
evaporate at 5 
o
C.  After eleven days, yellow plates of the OLAPHBNZ.IPA.H2O were 
collected by gravimetric filtration and dried at room temperature.  
 
3.2.3 Methods 
Powder X-ray diffraction (PXRD): Bulk samples were analyzed by powder X-ray 
diffraction with a Bruker AXS D8 powder diffractometer. Experimental conditions: Cu 
Kα radiation (λ = 1.54056 Ǻ); 40 kV; 30 mA; scanning interval 3–40° 2θ; time per step 
0.5s. The experimental PXRD patterns and calculated PXRD patterns from single crystal 
structures were compared to confirm that the composition of the bulk materials was 
consistent with that of the single crystal used for X-ray crystallography. 
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Single Crystal X-ray Diffraction Analysis: Single crystal X-ray data were collected 
using Bruker-AXS SMART-APEXII CCD diffractometer using CuKα radiation, λ = 
1.54178 Å for OLASAM.IPOAc.H2O and Mo Kα radiation (λ = 0.71073 Å) for 
OLANAM.IPOAc.H2O. Indexing was performed using APEX2
34
 (Difference Vectors 
method). Data integration and reduction were performed using SaintPlus 6.01.
35
  
Absorption correction was performed by multi-scan method implemented in SADABS.
36
   
Space groups were determined using XPREP implemented in APEX2.  The structure was 
solved using SHELXS-97 (direct methods) and refined using SHELXL-97 (full-matrix 
least-squares on F2) contained in APEX2 and WinGX v1.70.01
37 , 38 , 39 , 40
 [4,5,6,7] 
programs packages. All non-hydrogen atoms were refined anisotropically. 
Hydrogen atoms of water molecules and –NH groups for OLANAM.IPOAc.H2O were 
found in the Fourier difference map and included in the refinement process using distance 
restraints (DFIX) with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-NH,-OH). All 
remaining hydrogen atoms were placed in geometrically calculated positions and 
included in the refinement process using riding model with isotropic thermal parameters: 
Uiso(H) = 1.2Ueq(-CH, -CH2), Uiso(H) = 1.5Ueq(-OH, -CH3).   
Hydrogen atoms of water molecules and –NH groups for OLASAM.IPOAc.H2O were 
found in the Fourier difference map and included in the refinement process using distance 
restraints (DFIX, SADI) with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-NH,-OH). 
All remaining hydrogen atoms were placed in geometrically calculated positions and 
included in the refinement process using riding model with isotropic thermal parameters: 
Uiso(H) = 1.2Ueq(-CH, -CH2), Uiso(H) = 1.5Ueq(-OH, -CH3).  Crystallographic data 
and hydrogen bond parameters are presented in the appendix 4. 
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3.3 Results  
Crystal Structures of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O:  
OLANAM.IPA.4H2O and OLASAM.IPA.4H2O crystallize in the monoclinic space 
group P21/c where each cocrystal contain two OLA molecules, four water molecules, an 
isopropyl acetate molecule and one molecule of the cocrystal former (NAM or SAM).  
The crystal structures of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O reveal a two-
dimensional hydrogen-bonded network where four water molecules hydrogen bond to 
each other to form a tetrameric catemer.  This tetrameric catemer interacts with four 
OLA molecules by donating four hydrogen bonds and accepting two hydrogen bonds 
(Figs. 3.2a and 3.2b).  The isopropyl acetate molecules and the NAM/ SAM terminate the 
tetrameric catemer of water molecules via OH
…
O and NH
…
O hydrogen bond 
interactions.  NAM/ SAM molecules form amide homodimers along the c axis (Figs. 3.3a 
and 3.3b).  Olanzapine molecules are aligned in a herring bone pattern and are stacked in 
an eclipsed fashion (Figs. 3.4a and 3.4b).  Single crystals suitable for X-ray structure 
determination were not obtained for OLAPHBNZ.IPA.4H2O.   However, 
OLAPHBNZ.IPOAc.4H2O is presumably isostructural to OLANAM.IPA.4H2O and 
OLASAM.IPA.4H2O since the powder pattern obtained was found to be similar to the 
powder patterns of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O (appendix 4).   
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     (a)  (b)  
Figure 3.2:  Crystal packing view along a axis of (a) OLANAM.IPA.4H2O and (b) 
OLASAM.IPA.4H2O exhibiting a tetrameric catemer of water molecules that is 
hydrogen bonded to four OLA molecules.  The tetrameric catemer of water molecules 
offers 4 hydrogen bond donors and 2 hydrogen bond acceptors to complement a pair of 
olanzapine molecules.  The isopropyl acetate and the cocrystal former (NAM or SAM) 
hydrogen bond to each side of the tetrameric catemer of water molecules. 
 
 
 
 
  (a) (b)  
Figure 3.3:  Crystal packing view along c axis of OLANAM.IPA.4H2O and (b) 
OLASAM.IPA.4H2O showing how the tetrameric catemers of water molecules are 
terminated by the cocrystal former (NAM or SAM).  The NAM and SAM molecules 
form dimers to extend the structure.  In each case, two olanzapine molecules are omitted 
for clarity. 
 
 
 
 
 
76 
 
(a) (b)  
 
Figure 3.4:  Crystal packing of OLANAM.IPA.4H2O and (b) OLASAM.IPA.4H2O 
showing a herring bone pattern of pairs of olanzapine enantiomers hydrogen bonded to 
four water molecules.  NAM, SAM and isopropyl acetate molecules omitted for clarity. 
 
Anhydrate 
 
UNOGIN 
UNOGIN01 
 
Dihydrate 
 
AQOMAU 
AQOMAU01 
AQOMAU02 
 
Sesquihydrate 
 
AQOMEY 
AQOMEY01 
 
Solvates 
 
UNOGOT  
(methanol) 
 
WEXQAS 
(dichloromethane) 
 
Mixed hydrates and solvates 
 
CAYTUS 
(DMSO monohydrate) 
 
ELEVOG 
(methanol monohydrate) 
 
WEXPUL 
(butan-2-ol monohydrate) 
 
WEXQEW 
(ethanol dihydrate) 
Salts 
 
JIXROY  
(olanzapinium benzoate) 
 
TAQNUV  
(olanzapinium nicotinate) 
 
AMIYUR 
(olanzapinium maleate 
(1:1)) 
 
AMIZAY  
(olanzapinium maleate 
(1:2)) 
 
Table 3.1: Refcodes for crystal structures of olanzapine deposited in the CSD. 
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Figure 3.5:  Crystal packing of olanzapine anhydrate form I showing olanzapine 
enantiomers sustained by NH
…
N hydrogen bond interactions along the c axis. 
 
3.4 Discussion 
A critical step in the design of cocrystals is the study of crystal packing and hydrogen 
bonding patterns exhibited within the crystal structure of the target molecule. Analysis of 
the crystal structures of olanzapine deposited in the CSD reveals an anhydrate; three 
polymorphs of olanzapine dihydrate; two polymorphs of olanzapine sesquihydrate; 
methanol and dichloromethane solvates; four mixed solvates and hydrates; and salts with 
benzoate, nicotinate and maleate anions (Table 3.1).  Observation of the crystal packing 
in the crystal forms of olanzapine reveals pairs of olanzapine molecules where olanzapine 
adopts mirror-related conformations.
41
  In olanzapine anhydrate, these pairs of olanzapine 
molecules are connected by NH
…
N hydrogen bond interactions (Fig. 3.5).  However in 
the solvated and salt forms of olanzapine, the NH
…
N interaction is disrupted by solvent 
molecules or anions occupying sites between the pairs of olanzapine molecules.  
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Many of these crystal forms are isostructural and can be categorized according to 
their crystal packing arrangement and crystallographic unit cell parameters are denoted 
packing A, packing B, packing C and packing D (Tables 4-7).   
Packing A is exhibited in the crystal structure of olanzapine dihydrate form D 
(AQOMAU, Fig. 3.7).  In packing A, supramolecular heterosynthon 1 (Fig. 3.6a) is 
observed where the water molecules are arranged as a cyclic tetramer between the pairs 
of olanzapine molecules such that it offers four hydrogen bond donors and two hydrogen 
bond acceptors.  The number of hydrogen bond donors and acceptors is complementary 
to a pair of olanzapine molecules since olanzapine possesses one hydrogen bond donor 
and two hydrogen bond acceptors.  The pairs of olanzapine molecules form a herring 
bone pattern and the sheets are eclipsed to each other (Fig. 3.7b). 
Packing B is exhibited in three isostructural crystal forms of olanzapine:  AQOMAU01 
(dihydrate form B), AQOMEY01 (sesquihydrate form II) and UNOGOT (methanol 
solvate).  Packing B exhibits a three dimensional network where the solvent molecules lie 
between pairs of olanzapine molecules and hydrogen bonds to four olanzapine molecules 
(Figure 3.8).   In all three crystal forms, the pairs of olanzapine molecules are aligned 
along the crystallographic a axis in a herring bone pattern to form sheets that are stacked 
in an eclipsed manner.  Supramolecular heterosynthon 2 (Fig. 3.6b) is observed in the 
hydrated crystal forms AQOMAU01 and AQOMEY01 where the water molecules are 
arranged as a catamer and offers the same number of hydrogen bond donors and 
acceptors similar to supramolecular synthon 1 to match a pair of olanzapine molecules.  
In the methanol solvate (UNOGOT), a pair of methanol molecules lies between the pairs 
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of olanzapine molecules and hydrogen bonds to four olanzapine molecules via NH…O 
and OH…O interactions.   
Packing C is exhibited in various crystal forms:  AQOMEY (sesquihydrate form I), 
AQOMAU02 (dihydrate form E), CAYTUS (DMSO solvate) and ELEVOG (methanol 
monohydrate).  Similar to packing A and B, the solvent molecules occupy sites between 
the pairs of olanzapine molecules to form bridges that hydrogen bonds to four olanzapine 
molecules.  Supramolecular heterosynthon 2 is also observed in the hydrated crystal 
forms.  The difference between packing B and packing C is the orientation of adjacent 
sheets where they are stacked in a staggered fashion (Figure 3.9).    
Packing D is exhibited in salts of olanzapine with benzoate (JIXROY) and nicotinate 
(TAQNUV) anions.  Analysis of the crystal structures reveals the alignment of the pairs 
of olanzapine molecules along the c axis (Figure 3.10).  The pairs of olanzapine 
molecules are connected via charge assisted interactions formed between the carboxylate 
of the benzoate and nicotinate anion and the ammonium of the olanzapine cation.  
 
Figure 3.6: Two types of supramolecular heterosynthon exhibited in crystal structures of 
olanzapine dihydrate. 
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REF 
CODE 
Compo
und 
a (Å) b (Å) c (Å) α (o) β (o) 
 
γ (o) Volum
e 
Space 
Grou
p 
AQOM
AU  
Dihydr
ate 
9.927 
(5)  
 
10.095 
(5)  
 
10.514 
(6)  
 
84.71 
(1) 
62.66 
(<1)  
 
71.18 
(<1) 
884.00
1 
 
P-1  
 
Table 3.2:  Crystal forms of olanzapine that exhibits packing A. 
 
REF 
CODE 
Comp
ound 
a (Å) b (Å) c (Å) α (o) β (o) 
 
γ (o) Volu
me 
Space 
Group 
AQOM
EY01 
Sesqui
hydrat
e 
10.040 
(2) 
 
12.900 
(3) 
 
14.510 
(3) 
 
90 92.97 
(<1) 
 
90 1802.8
10 
 
P21/c 
 
AQOM
AU01 
Dihyd
rate 
9.869 
(1) 
 
12.716 
(1) 
 
14.385 
(1) 
 
90 92.97 
(<1) 
 
90 1802.8
10 
 
P21/c 
 
UNOG
OT 
Metha
nol 
solvat
e 
10.207 
(3) 
 
12.440 
(4) 
 
14.278 
(5) 
 
90 92.60 
(3) 
 
90 1811.0
84 
 
P21/c 
 
Table 3.3:  Crystal forms of olanzapine that exhibits packing B. 
 
REF 
CODE 
Comp
ound 
a (Å) b (Å) c (Å) α (o) β (o) 
 
γ (o) 
 
Volu
me 
Space 
Group 
AQOME
Y 
Sesqui
hydrat
e 
25.130
9 (2) 
12.238 
(1) 
 
14.912 
(1) 
90 124.98 
(<1) 
 
90 3757.2
14 
 
C2/c 
 
AQOMA
U02 
Dihyd
rate 
24.520 12.350 15.218 90 125.82 
 
90 3736.2
81 
 
C2/c 
 
CAYTU
S 
DMS
O 
solvat
e 
24.584 
(4) 
12.534 
(1) 
 
15.153 
(3) 
90 125.45 
(1) 
 
90 3803.4
30 
 
C2/c 
 
ELEVO
G 
Metha
nol 
monoh
ydrate 
25.359 
(<1) 
11.973 
(<1) 
15.609 
(<1) 
90 127.58 
(<1) 
 
90 3753.7
71 
 
C2/c 
 
Table 3.4:  Crystal forms of olanzapine that exhibits packing C. 
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REF 
CODE 
Comp
ound 
a (Å) b (Å) c (Å) α (o) 
 
β (o) 
 
γ (o) 
 
 
Volu
me 
Space 
Group 
TAQNU
V 
 
Olana
zapine 
nicotin
ate 
9.296 
(1) 
11.242 
(1) 
 
12.000 
(1) 
 
63.16 
(<1) 
 
87.48 
(<1) 
 
83.73 
(<1) 
 
1111.4
42 
 
P-1 
 
JIXROY 
 
Olanz
apine 
benzo
ate 
9.257 11.222 
 
12.063 
 
64.59 
(<1) 
 
87.57 
(<1) 
 
83.25 
(<1) 
 
1124.7
53 
 
P-1 
 
Table 3.5:  Crystal forms of olanzapine that exhibits packing D. 
 
 
  (a) (b)  
Figure 3.7:  (a) Crystal structure of olanzapine dihydrate form D exhibiting packing A 
where a cyclic tetramer of water molecules hydrogen bonds to four olanzapine molecules 
along the b axis.  (b) Sheets of olanzapine molecules eclipse one another; water 
molecules deleted for clarity. 
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   (a)  (b)  
 
   (c)   (d)  
Figure 3.8:  Crystal packing of (a) olanzapine dihydrate form B (b) olanzapine 
sesquihydrate form II and (c) olanzapine methanol solvate exhibiting packing B, wherein 
the solvent molecules are arranged such that they hydrogen bond to four olanzapine 
molecules. (d) Illustrates sheets that are arranged in a herring bone pattern and stack in an 
eclipsed manner; solvent molecules deleted for clarity. 
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     (a) (b)  
 
     (c) (d)  
Figure 3.9:  Crystal forms of (a) olanzapine sesquihydrate form I (b) olanzapine DMSO 
solvate and (c) olanzapine methanol monohydrate exhibiting packing C where the solvent 
molecules form bridges to hydrogen bond to four olanzapine molecules.  (d) Illustrates 
adjacent sheets that stack in a staggered manner; solvent molecules deleted for clarity. 
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(a)  
(b)  
Figure 3.10:  Packing D exhibiting olanzapine cation interacts with nicotinate and 
benzoate anions via charge assisted NH
…
COO
-
 hydrogen bonds along the a axis. 
 
Crystal Engineering of Isostructural Cocrystals of Olanzapine:  The formation of 
centrosymmetric pairs of olanzapine molecules is observed in crystal forms that exhibit 
packing A, B, C and D.  Analysis of these crystal forms reveals the solvent molecules 
always arrange themselves between pairs of olanzapine molecules and hydrogen bonds to 
four olanzapine molecules irrespective of the solvent molecule.  It has been asserted that 
water molecules are promiscuous in terms of the supramolecular synthons they it exhibit, 
as well as resulting structural stability and stoichiometry.
42
  Indeed, the water molecule 
has been described as chameleon-like due to its small size and versatile hydrogen 
bonding capabilities.  For example, gallic acid monohydrate, the first tetramorphic 
hydrate for which fractional coordinates have been determined, exhibits different 
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supramolecular synthons and crystal packing in each polymorph.  In contrast, analysis of 
the polymorphic forms of olanzapine dihydrate for which coordinates have been 
determined reveals that the water molecules arrange to offer four hydrogen bond donors 
and two acceptors to complement a pair of olanzapine molecules (Figure 5).  Therefore, it 
can be presumed that the pairs of olanzapine molecules are the supramolecular building 
blocks of the crystal structure and therefore dictate the supramolecular assembly of the 
other components within the crystal.  This supramolecular building block was therefore 
exploited to yield isostructural cocrystals of olanzapine consisting of four chemical 
entities:  olanzapine, the cocrystal former, an iso-propyl acetate solvent molecule and 
four water molecules.   
Crystal structures of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O  reveal the 
presence of a tetrameric catemer of water molecules as exhibited in the solvated crystal 
forms of olanzapine.  The presence of this tetrameric catemer of water molecules within 
the crystal lattice results in an imbalance of the number of hydrogen bond donors and 
acceptors such that there is an excess of a single hydrogen bond donor and a hydrogen 
bond acceptor.  The excess hydrogen bond donor and acceptor become satisfied by the 
incorporation of the solvent molecule and the cocrystal former to afford four hydrogen 
bond donors and two hydrogen bond acceptors to match a pair of olanzapine molecules.  
The underlying principle in the synthesis of isostructural cocrystals of olanzapine is that 
the persistence of the pairs of olanzapine molecules and the tetrameric catemer of water 
molecules allows for the substitution of cocrystal formers that are structurally consistent 
without altering the crystal packing.   
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 No. of entries % of structures 
Total number of entries 152 100 
Entries where one chemical 
entity is a solid at ambient 
temperature 
45 29.6 
Entries with two chemical 
entities that are solids at 
ambient temperature 
85 55.9 
Entries with three chemical 
entities that are solids at 
ambient temperature 
17 11.1 
Entries with four chemical 
entities that are solids at 
ambient temperature 
5 3.8 
* Conquest 1.13, Nov 2011 update, only organics, 3D coordinates known, R ≤ 7.5, No 
ions. 
Table 3.6: CSD statistics of crystal forms containing four distinct molecular chemical 
entities. 
 
CSD statistics of crystal structures that contain four distinct molecular chemical 
entities 
A CSD analysis was conducted to evaluate the number of crystal forms that 
contains four distinct chemical entities to reveal a total of 152 hits.  These structures were 
further divided into four categories where at least 1 component was solid, at least two 
components were solid, at least three components were solid and at least four components 
were solid (Table 3.6).   
There are 45 entries where one chemical entity was solid at ambient temperature 
whereas 85 of the 152 entries fall into the category where at least two chemical entities 
are solid at ambient temperature.  Analysis of the categories where all three and four 
chemical entities are solid reveals 17 and 5 entries respectively.  Cocrystals of olanzapine 
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reported herein fall into the category where two chemical entities are solid at ambient 
temperature.  Of the 152 entries, only three crystal forms, MESRUX, OHUXAQ and 
POHXUG contain a molecule that exhibits biological activity.  OHUXAG contains only 
one molecule that is solid at room temperature and MESRUX and POHXUG contains 
two and three molecules that are solid at room temperature respectively.  Analysis of 
crystal forms containing four chemical entities reported in the CSD reveal that few 
exhibit isostructurality, notably CIKWAV, CIKWEZ, CIKWED (where two chemical 
entities are solid), ROBHAS, ROBHEW, ROBHIA (where three chemical entities are 
solid), QUFZIB and QUFZOH (where four chemical entities are solid).  Most of these 
structures are host-guest inclusion compounds where isostructurality is achieved through 
the exchange of guest molecules that are loosely held in the crystal structure.  A literature 
survey of isostructural cocrystals reveals mainly two component crystal forms sustained 
by hydrogen and halogen bonding networks.
32, 43
  Indeed it has been reported that 
isostructural structures rarely include more than two members due to the close packing of 
molecules in crystalline solids.
44
  However to the best of our knowledge, this is the first 
reported isostructural four component crystal forms that contain water and solvent 
molecules.  
 
3.5 Conclusion 
 In summary, this study has shown how the systematic analysis and understanding 
of existing crystal structures of olanzapine facilitates the synthesis of four component 
isostructural cocrystals of olanzapine.  These cocrystals are relevant as they illustrate that 
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in general crystal structures of APIs can be deliberately designed and their 
physicochemical properties can be systematically customized. 
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Summary 
The increasing number of poorly soluble new drug candidates has challenged the 
pharmaceutical industry to develop new drug delivery technologies.  Pharmaceutical 
cocrystals have become an inherent part of drug development as it is one means to 
improve the physicochemical and biopharmaceutical properties of the API.  As 
pharmaceutical cocrystals play an active role in drug development strategies, several 
issues such as their design i.e. the selection of cocrystals former libraries, the challenges 
that arise in their design and scale up become of interest. 
 The research herein focuses on the design of cocrystals in the context of the 
selection of the cocrystals former libraries.  Typically, cocrystals former libraries include 
pharmaceutically acceptable carboxylic acids however this can be expanded to include 
compounds such as nutraceuticals, zwitterions and inorganic salts.  The phenolic acids, 
gallic acid and ferulic acid (a subclass of nutraceuticals) were used as model compounds 
since they possess the functional moieties carboxylic acid and phenols.  These functional 
moieties readily engage in molecular recognition events with complementary functional 
groups basic nitrogen, amides and carbonyls.     Therefore, based on the statistical success 
rate of supramolecular heterosynthons formed between these complementary functional 
moieties and using the concepts of self-assembly, cocrystals formers were selected.  The 
six cocrystals formers selected yielded 6 pairs of cocrystals with the compounds gallic 
acid and ferulic acid respectively.  Studies of the crystal packing and supramolecular 
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synthons of these cocrystals revealed the hierarchical nature of the COOH
…
Nbasic 
supramolecular heterosynthon.  This study has shown that cocrystals can be designed by 
first principles of crystal engineering using the concepts of supramolecular chemistry and 
self-assembly.  It reiterates the fact that a detailed understanding of the supramolecular 
synthons formed between functional groups is pivotal in the design of cocrystals.   
However, this strategy falls short when a molecule possesses multiple functional groups 
and exhibits conformational flexibility.   
A crystal engineering strategy was developed to address such compounds using 
the model compound, olanzapine.  This design strategy included a comprehensive 
analysis of the crystal packing of existing crystal forms of olanzapine.  Analysis of the 
crystal forms of olanzapine deposited in the Cambridge Structural Database (CSD) 
revealed four types of crystal packing.  In addition, analysis of the hydrated crystal forms 
of olanzapine revealed that the water molecules are arranged such that the number of 
hydrogen bond donors and acceptors is complementary to a pair of olanzapine molecules.  
This understanding was advantageous to afford four quaternary isostructural multi-
component crystal forms of olanzapine.  These crystal forms consist of olanzapine, the 
cocrystals former, an iso-propyl acetate solvent molecule and a water molecule.  These 
cocrystals are relevant as they illustrate that in general crystal structures of APIs can be 
deliberately designed and their physicochemical properties can be systematically 
customized. 
The role of water molecules in crystal engineering was investigated in terms of 
the nemesis it presents in the design of crystal forms.  Although hydrates represent 10% 
of the crystal structures archived in the CSD and numerous hydrates are known for a 
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given compound, the question is asked, “In general, can a hydrate be synthesized or 
designed intentionally?”  In other words, is there anything predictable about hydrates, 
that is, their preparation, thermal stability or the supramolecular synthons they exhibit.  A 
series of cocrystals hydrates were investigated and were categorized according to the 
thermal property they exhibit.  In addition, a Cambridge Structural Database (CSD) 
analysis was conducted in order to address the supramolecular heterosynthons that water 
molecules exhibit with two of the most relevant functional groups in the context of active 
pharmaceutical ingredients, carboxylic acids, and alcohols.  It was concluded that there 
was no correlation between the crystal structure and the thermal stability exist in any of 
the other categories of hydrate.  The CSD analysis suggests that, unlike cocrystals, there 
is great diversity in the supramolecular heterosynthons exhibited by water molecules 
when they form hydrogen bonds with carboxylic acids or alcohols.  
That hydrates can be regarded as the nemesis in crystal engineering can be 
reiterated by the isolation of two polymorphic forms of gallic acid monohydrate to give 
the first tetramorphic hydrate for which fractional coordinates have been determined.  
Analysis of the crystal packing in each form revealed significantly different hydrogen 
bonding patterns.  Moreover, a CSD survey of polymorphic hydrates exhibited different 
supramolecular synthons with respect to the water molecule.  Therefore, the promiscuity 
of hydrates in terms of the supramolecular synthons they exhibit or their thermal stability 
reveals the challenges in crystal engineering. 
Future direction should focus on the advancement of the understanding of 
cocrystal formation.  In addition to the expansion of cocrystal formers, incorporating 
phase solubility diagrams is relevant since it defines the thermodynamically stable region 
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of the cocrystal in relation to its pure components.  Emphasis must be placed on the 
physical stability of cocrystals in order to develop scale-up procedures in the manufacture 
of cocrystals.  Focus should be placed on the low cost scale-up of the cocrystal without 
changing its optimized properties and reproducibility. 
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Appendix 4:  Supplementary Information:   A Crystal Engineering Study of Gallic 
Acid and Ferulic Acid as Cocrystal Formers 
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Gallic Acid•Adenine, GALADN 
 
PXRD of GALADN 
 
IR of GALADN 
 
DSC of GALADN 
Gallic Acid•Urea, GALURE 
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PXRD of GALURE 
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DSC of GALURE 
Gallic Acid•Glycine Anhydride, GALGAH 
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PXRD of GALGAH 
 
IR of GALGAH 
 
DSC of DSC 
Ferulic Acid• Adenine, FERADN 
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PXRD of FERADN 
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Ferulic Acid•Isoniazid, FERINZ 
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PXRD of FERDMP 
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Ferulic Acid•Urea, FERURE 
 
PXRD of FERURE 
 
IR of FERURE 
 
DSC of FERURE 
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Ferulic Acid•Glycine Anhydride, FERGAH 
 
PXRD of FERGAH 
 
IR of FERGAH 
 
DSC of FERGAH 
 
Ferulic Acid• Theobromine, FERTBR 
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Appendix 5:  Supplementary Information:   Crystal Engineering of Isostructural 
Quaternary Multi-Component Crystal Forms of Olanzapine. 
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PXRD of Olanzapine Nicotinamide Isopropyl acetate Tetrahydrate, 
OLANAM.IPOAc.H2O 
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PXRD of Olanzapine p-Hydroxybenzamide  Isopropyl acetate Tetrahydrate,  
OLAPHBNZ.IPOAc.H2O 
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 OLANAM.IPA.4H2O OLASAM.IPA.4H2O 
Formula C45H64N10O7S2 C45H64N10O8S2 
MW 
(g/mol) 
921.18 
937.17 
 
Crystal 
system 
monoclinic monoclinic 
Space 
group 
P21/c P21/c 
a  (Å) 14.0961 (12) 14.1966(7) 
b (Å) 12.5984 (10) 12.5375(6) 
c (Å) 27.219 (2) 27.4599(15) 
α (deg) 90 90 
β (deg) 97.396 (2) 96.579(3) 
γ (deg) 90 90 
V / A
3
 4793.6 (7) 4855.4 
Dc/g cm
-3
 1.276  
Z 4 4 
2θ range 1.46 to 25.04 3.13 to 67.47 
Nref./Npar
a 
8457/620 8186 / 594 
T /K 100(2) 100(2) 
R1 [I>2σ 
(I)] 
0.0676 0.0698 
wR2 0.1687 0.2120 
GOF 1.018 1.010 
Abs coef 0.171 1.492 
 
Table 1: Crystallographic data and structure refinement parameters for cocrystals of 
olanzapine. 
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 Hydrogen 
bond 
d (H · · · A) /Å D (D · · · A)/Å <(DHA) 
OLANAM.IPOAc.H2O N-HO 2.01(2) 2.878(4) 170(4) 
N-HO 1.99(2) 2.865(4) 168(3) 
N-HO 1.91(2) 2.829(4) 172(4) 
N-HO 2.02(2) 2.926(4) 173(4) 
O-HO 2.034(18) 2.909(4) 175(4) 
O-HO 1.916(18) 2.771(4) 168(3) 
O-HO 2.110(18) 2.956(4) 172(4) 
O-HO 1.99(2) 2.840(4) 160(4) 
O-HN 1.94(2) 2.764(4) 168(3) 
O-HN 1.901(18) 2.772(4) 175(4) 
O-HN 2.043(18) 2.896(4) 173(4) 
O-HN 2.07(2) 2.939(4) 173(4) 
OLASAM.IPOAc.H2O N-HO 2.02(2) 2.894(4) 169(5) 
N-HO 2.03(3) 2.881(4) 160(4) 
N-HO 2.068(2) 2.958(5) 177(6) 
N-HO 1.94(3) 2.812(5) 161(6) 
O-HO 1.90 2.620(5) 143.7 
O-HO 2.061(1) 2.922(4) 173(4) 
O-HO 2.08(3) 2.847(4) 146(5) 
O-HO 1.924(1) 2.783(4) 172(4) 
O-HO 2.142(2) 2.976(5) 162(4) 
O-HN 1.890(2) 2.750(4) 168(4) 
O-HN 2.16(2) 2.984(5) 160(4) 
O-HN 1.926(1) 2.790(5) 176(5) 
O-HN 2.049(2) 2.899(4) 167(5) 
Table 2:  Selected hydrogen bond distances and parameters of cocrystals 
 
